

L20 ANSWER 7 OF 47

ACCESSION NUMBER:

TITLE (ENGLISH):

TITLE (FRENCH):

INVENTOR(S):

PATENT ASSIGNEE(S):

LANGUAGE OF PUBL.:

DOCUMENT TYPE:

PATENT INFORMATION:

PCTFULL COPYRIGHT 2003 Univentio  
1996015249 PCTFULL ED 20020514

HIGH LEVEL EXPRESSION AND FACILE PURIFICATION OF  
PROTEINS, PEPTIDES AND CONJUGATES FOR IMMUNIZATION,  
PURIFICATION AND DETECTION APPLICATIONS  
EXPRESSION A HAUT NIVEAU ET PURIFICATION AISEE DE  
PROTEINES, PEPTIDES ET CONJUGUES UTILISES DANS DES  
APPLICATIONS D'IMMUNISATION, PURIFICATION ET DETECTION

KNUTH, Mark, W.;  
HAAK-FRENDSCO, Mary;  
SHULTZ, John, W.;  
LESLEY, Scott, A.;  
VILLARS, Catherine, E.  
PROMEGA CORPORATION  
English  
Patent

NUMBER KIND DATE

DESIGNATED STATES

W:

WO 9615249

A1 19960523

AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB  
GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK  
MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA  
UG UZ VN KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR  
IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE  
SN TD TG

APPLICATION INFO.:

PRIORITY INFO.:

PI WO 9615249

WO 1995-US14518 A 19951113  
US 1994-8/338,382 19941110

A1 19960523

DETD . . . of or

insertion in the polypeptide chain to form a fusion protein  
defined below, and/or which may be chemically coupled to a  
peptide, **haptén**, or other **ligand** to form a carrier  
protein

**conjugate** defined below, and/or which may be coadministered  
with an antigen as described under coadministration. 11 The  
carrier protein will generally have a . . .

Hybridoma cells then may be prepared by fusing  
lymphoid organ cells from an immunized animal with a **tumor**  
cell. Appropriately secreting hybridoma cells may  
thereafter be selected (Kohler & Milstein, 1976).

CLMEN 17 The carrier protein **conjugate** of claim 14 wherein  
the **ligand** is a **haptén**.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>C12N 15/62, 15/63, C07K 14/01, C12N 1/21, C07K 9/00, A61K 39/12, C07K 16/42, G01N 33/566, C12Q 1/25</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/15249</b> <b>(43) International Publication Date:</b> 23 May 1996 (23.05.96)
<b>(21) International Application Number:</b> PCT/US95/14518 <b>(22) International Filing Date:</b> 13 November 1995 (13.11.95) <b>(30) Priority Data:</b> 08/338,382 10 November 1994 (10.11.94) US <b>(71) Applicant:</b> PROMEGA CORPORATION [US/US]; 2800 Woods Hollow Road, Madison, WI 53711-5399 (US). <b>(72) Inventors:</b> KNUTH, Mark, W.; 7154 Hickory Run, Waunakee, WI 53597 (US). HAAK-FRENDSCHO, Mary; 2800 Rosellen Avenue, Madison, WI 53711 (US). SHULTZ, John, W.; 407 Melody Lane, Verona, WI 53593 (US). LESLEY, Scott, A.; 135 Village View Court, Oregon, WI 53575 (US). VILLARS, Catherine, E.; 6202 Rivercrest Drive, McFarland, WI 53558 (US). <b>(74) Agent:</b> SARA, Charles, S.; Dewitt, Ross & Stevens, S.C., 8000 Excelsior Drive, Madison, WI 53717-1914 (US).	<b>(81) Designated States:</b> AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> HIGH LEVEL EXPRESSION AND FACILE PURIFICATION OF PROTEINS, PEPTIDES AND CONJUGATES FOR IMMUNIZATION, PURIFICATION AND DETECTION APPLICATIONS		
<b>(57) Abstract</b>  A process for producing and purifying peptides and for producing peptide/protein antigens for antibody production is described. The process utilizes fusion proteins and specifically fusion proteins in which the fusion protein carrier segment includes an amino acid sequence at least about 65 amino acids long and in which the amino acid sequence does not contain negative or positive charged side chains of amino acids.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**HIGH LEVEL EXPRESSION AND FACILE PURIFICATION OF  
PROTEINS, PEPTIDES AND CONJUGATES FOR IMMUNIZATION,  
PURIFICATION AND DETECTION APPLICATIONS**

**FIELD OF THE INVENTION**

Generally, the present invention is directed to the field of recombinant DNA technology. More particularly the present invention is directed to a process for producing and purifying peptides for multiple uses and producing  
5 antigens for antibody production. The present invention also is directed to the high level expression of small to medium sized ligands utilizing recombinant DNA technology. Specifically, the present invention is directed to an antigen production system utilizing fusion proteins. The  
10 present invention also is directed to an efficient method for presenting an antigen to an animal or human immune system.

**CITED REFERENCES**

15 A full bibliographic citation of the references cited in this application can be found in the section preceding the claims.

**DESCRIPTION OF THE PRIOR ART**

20 The present invention generally relates to markets where the detection or purification of molecules is involved. Representative markets include *in vitro* and *in vivo* diagnostics, research products, clinical products, clinical research products, pharmaceuticals and many  
25 industrial markets. These markets necessarily require a tight binding and specific affinity ligand that recognizes the biomolecule of interest. Given the importance of affinity recognition for proteins in a wide variety of markets, new methods for generating "immunoaffinity" or  
30 "macromolecular recognition" ligands using DNA technology are sought.

The production of proteins and peptides by recombinant DNA technology is now relatively common. Recombinant expression of peptides often is accomplished by inserting  
35 a DNA sequence encoding the desired peptide into an

expression vector. The expression vector generally contains regulatory sequences which are recognized by the host cell, and which provide for transcription and translation of the inserted DNA to produce the peptide.

5 The expression vector is inserted into a suitable whole cell, typically a procaryotic organism, in culture. The expression vector also usually includes a selectable marker, so that one may identify those cells which have been transformed successfully and carry the vector, and

10 separate them from those which do not carry the vector.

Peptides may be expressed either directly or in the form of a fusion protein. Direct expression involves the production of the desired protein or peptide without modification. However, this form of expression often

15 results in low yields and degradation of the product, particularly with small peptides.

One method commonly employed to increase the yield of the desired peptide is to express it as part of a fusion protein. In this approach, a leader protein, hereafter

20 referred to as a carrier segment, is selected which is expressed easily in the host of choice. Often this protein is native to the host, as in the case of  $\beta$ -galactosidase. An expression vector encoding the carrier segment then is modified using standard molecular cloning techniques to

25 express the desired peptide linked to the carrier segment. Most often, the peptide is linked to the carboxy terminus of the carrier segment but, in principle, it could be linked anywhere through a normal peptide linkage.

The expression of the peptide as a fusion protein with

30 the carrier segment may imbue it with new, favorable properties. For instance, the fusion protein can be injected into a host animal to create antibodies to the peptide or to produce a vaccine. The technology of using fusion proteins as antigens is well-known to the art

35 (Current Protocols, 1994, Chapter 16). Other favorable properties of the fusion protein may include ease of purification, the ability to be immobilized on surfaces,

and the creation of bifunctional molecules (*Santo, C. et al.* 1992).

Although peptides with desired additional properties are commonly produced by the use of fusion proteins, it is  
5 also common to produce a peptide separately through chemical synthesis. The peptide then can be covalently coupled to purified carrier segments using chemical crosslinking agents. The resultant carrier protein conjugate can be used in many of the same applications as  
10 the fusion protein described above.

For example, peptides are sometimes covalently coupled to keyhole limpet hemocyanin for immunizations or to alkaline phosphatase for use as a detection reagent. In the case of the fusion protein, the only molecules which  
15 can be linked to the carrier segment are peptides, and the linkage must be through the normal polypeptide backbone.

When the second molecule is coupled chemically to the carrier segment after expression, the nature of both the second molecules, called ligands, and of the chemical  
20 linkages to the carrier segment is much broader. Any ligand and crosslinker which is chemically allowed can be contemplated.

In some cases, covalent association of the ligand (peptide, hapten, or other) with the carrier segment is not  
25 required to be effective. The two molecules associate with each other by any number of means. In this case, the mixture of the two is called a carrier protein complex.

The following paragraphs illustrate some uses of prior art fusion proteins. For example, U.S. Patent 4,743,679 to  
30 Cohen et al. discloses the expression of epidermal growth factor (EGF) as a fusion protein with a leader sequence of up to 200 amino acids (preferably up to 75). The fusion protein is expressed in bacteria as an insoluble inclusion body.

35 U.S. Patent 5,302,526 to Keck et al. is directed to recombinant DNA encoding amphiphilic leader sequences (carrier segments) for the production and purification of

fusion proteins. The polypeptide comprises an amphophilic helix designed to have hydrophilic charged amino acid residues on one side and nonpolar amino acid residues on the other side of the helix. When a gene encoding a protein of interest is attached to the helix, an inclusion body is formed. The inclusion bodies may be collected and purified.

U.S. Patent 5,322,930 to Tarnowski et al. describes a method for expressing proteins as fusion proteins by using the portion of human pro-atrial natriuretic peptide (proATP) as the carrier for a heterologous peptide, wherein each of the Glu residues normally present in the proATP protein portion is altered to Gln.

U.S. Patent 5,008,373 to Kingsman et al. describes a fusion protein system useful in vaccines or in diagnostic or purification applications. The fusion protein includes a first amino acid sequence derived from a retrotransposon or an RNA retrovirus encoded for by a yeast TYA gene sequence. The second amino acid sequence is a biologically active amino acid sequence, acting as the antigen.

U.S. Patent 5,322,769 to Bolling, et al. is directed to a method for using CKS fusion proteins in assays.

Lin et al. (1987) disclose the use as an antigen of a fusion protein containing a carrier segment consisting of the gene 10 molecule of phage T7.

A major problem with prior art carrier segments is that the carrier segments also are known to be antigenic; that is, antibodies are produced in response to the carrier segment. Thus, there is a competition between the production of antibodies to the desired ligand and the production of antibodies to the carrier segment which may result in a lower production of antibodies with specificity for the target segment. Since the immune system usually reacts to surface exposed peptide segments which are often charged, it is likely that the existence of charged residues on the carrier segment exacerbates such problems with antigenicity.

Another problem with prior art carrier segments is that they often require the use of adjuvants. Adjuvants serve a variety of purposes (Klein, 1990). Adjuvants trap the antigen by causing the formation of an emulsion, precipitate or small vesicles at the injection site from which the antigen is released slowly over a prolonged period. The clearance of the antigen is thus delayed and the organism's exposure to the antigen is lengthened. Adjuvants also stimulate the nonspecific migration of cells to the site of antigen injection and increase the probability of interaction of the antigen with cells of the immune system. Further, adjuvants increase antigen dispersion in the recipient's body by continually delivering the antigen in small amounts from the injection site to the regional lymph nodes or spleen. Some adjuvants also have a mitogenic effect and so stimulate the proliferation of lymphocytes nonspecifically. Some adjuvants also help to stimulate lymphocytes by activating adenylate cyclase and other chemical messengers. Adjuvants may increase the probability of contact among T- and B-cells, macrophages, and antigens through the activation of lymphocyte-trapping mechanisms. The main problem with adjuvants is that some of the most effective ones tend to be toxic to and/or cause lesions in the host organism. They also can be difficult to handle.

#### SUMMARY OF THE INVENTION

The present invention is directed to a fusion protein carrier segment comprising a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence.

The present invention is also directed to a substantially nonantigenic fusion protein carrier segment comprising a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence having a length at least about 65 amino acids long, wherein the carrier segment comprises no more than approximately 5% of the



following amino acids: arginine, lysine, aspartic acid, glutamic acid, cysteine, tryptophan and methionine.

The present invention further is directed to a carrier protein conjugate comprising a first amino acid  
5 sequence, wherein the first amino acid sequence is at least about 65 amino acids long and the first amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine,  
10 lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site); and a ligand fused to the first amino acid sequence.

15 Further, the present invention is directed to an amino acid sequence as illustrated in Fig. 1 [SEQ. ID. 1] or to an amino acid sequence as illustrated in Fig. 3 [SEQ. ID. 2].

The present invention also is directed to a non-  
20 naturally occurring fusion compound comprising an amino acid sequence as illustrated in Fig. 1 [SEQ. ID. 1] linked to a ligand.

The present invention also is directed to an expression vector comprising an amino acid sequence in a  
25 single reading frame with a coding sequence for an antigen, wherein the expression vector expresses a particle-forming fusion protein encoded by the amino acid sequence and a ligand, wherein the amino acid sequence is a non-naturally occurring, hydrophobic, sparingly soluble amino acid  
30 sequence wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of  
35 the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site).

The present invention further is directed to an adjuvant for administering a high molecular weight protein to a host animal, the adjuvant comprising a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence.

The present invention also is directed to a process for producing an antibody to a ligand comprising: a) fusing a carrier segment comprising a non-naturally occurring hydrophobic sparingly soluble amino acid sequence to the ligand to form a fusion protein or carrier protein conjugate or carrier protein complex; b) presenting the antigen by *in vivo* or *in vitro* means; and c) producing the antibody to the ligand by *in vivo* or *in vitro* means.

The present invention also is directed to an assay for determining the concentration of an anti-antigen antibody in a test sample, wherein (a) at least a carrier protein conjugate is attached to a solid phase as capture reagent and is contacted with the test sample for a time and under conditions suitable for antigen/antibody or complexes to occur, and (b) an indicator reagent comprised of a signal generating compound and a specific binding member for the analyte is contacted with the complexes for time sufficient for a reaction to occur, wherein the signal generated is an indication of the presence of the anti-analyte antibody in the test sample. The improvement comprises attaching a fusion protein carrier segment comprising a non-naturally occurring hydrophobic sparingly soluble amino acid sequence to the solid phase as the capture reagent.

The present invention is further directed to a process for vaccinating a host vertebrate animal with an immunogen, comprising: (a) preparing an immunogen comprising a substantially nonantigenic fusion protein carrier segment containing a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence having a length at least about 65 amino acids long wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following

negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site); and (b) administering the carrier protein conjugate to the host vertebrate animal.

The present invention also is directed to a process for vaccinating a host vertebrate animal with an immunogen, comprising: (a) forming an immunogen comprising a non-naturally occurring carrier protein conjugate containing an amino acid sequence as illustrated in Fig. 1 [SEQ. ID. 1] and a ligand fused to the amino acid sequence; and (b) administering the carrier protein conjugate to the host vertebrate animal.

Further, the present invention is directed to a process for immunopurifying antibodies from a pool of antibody material, comprising: (a) forming a substantially nonantigenic fusion protein carrier segment containing a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence having a length at least about 65 amino acids long wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site); (b) incubating the antibody material with the carrier protein conjugate under binding conditions to bind the antibody material to the carrier protein conjugate to form an antibody/conjugate complex; (c) separating out the antibody/conjugate complex; (d) dissociating the antibody from the antibody/conjugate complex; and (e) separating the antibody from the antibody/conjugate complex.

Further, the present invention is directed to a process for producing peptides, comprising: (a) incubating a fusion protein containing a fusion protein carrier segment comprising a non-naturally occurring hydrophobic sparingly soluble amino acid sequence, wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site), under conditions where the peptide bonds on the fusion protein are cleaved; and (b) separating out the desired peptides.

Further, the present invention is directed to a protease inhibitor comprising a fusion protein containing a fusion protein carrier segment comprising a non-naturally occurring hydrophobic sparingly soluble amino acid sequence and a cleavage site for a protease, wherein the fusion protein is isolated and used as a competitive inhibitory substrate.

Further still, the present invention is directed to a solid support having absorbed thereon a carrier protein conjugate comprising: (a) a first amino acid carrier sequence, wherein the first amino acid sequence is at least about 65 amino acids long and the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site); and (b) a ligand fused to the first amino acid carrier sequence.

The present invention also is directed to an assay for determining the concentration of an enzyme in a test sample, wherein (a) at least a carrier protein conjugate

containing a ligand upon which the enzyme can act is attached to a solid phase and is contacted with the test sample for a time and under conditions suitable for the enzyme to act upon the substrate, and (b) indicator  
5 reagents capable of generating a signal change in response to the enzyme-catalyzed modification of the immobilized substrate is contacted with the complexes for time sufficient for a reaction to occur, wherein the signal generated is an indication of the presence of the enzyme in  
10 the test sample. The improvement comprises attaching a recombinant fusion protein carrier segment comprising a non-naturally occurring hydrophobic sparingly soluble amino acid sequence to the solid phase as the capture reagent.

The present invention also is directed to a test kit  
15 for use in detecting the presence of anti-antigen antibodies in a test sample, which test kit contains a container containing at least one protein specific for the anti-antigen antibody and, wherein the improvement comprises a container containing a non-naturally occurring  
20 hydrophobic sparingly soluble amino acid sequence, which is specific for the anti-antigen antibody.

The present invention also is directed to an immunoassay kit for detecting a specific antigen, comprising in separate containers:

- 25 a. a solid support having bound thereto one or more antibodies produced according to the process described above that will specifically react with a desired antigen;
- b. a buffer to remove unbound proteins;
- 30 c. solutions for detection of bound analyte; and
- d. instructions for use.

The advantages of the present invention are specifically directed to the novel carrier segment. Some  
35 of the advantages of the carrier segment are as follows:

**Low Antigenicity:** One of the primary goals of the present invention is to make antibodies to a ligand. In

order to have the best opportunity to make the antibodies to the ligand, the carrier segment portion of the fusion protein must be relatively nonantigenic to the animal. Typically, the immune system in a host body will target foreign materials, i.e., antigens presented to the system. When an antigen such as a fusion protein enters the body, the immune system will seek out the most antigenic moiety to attack. If the carrier segment happens to contain the most notable antigen, the immune system will preferentially target the carrier segment and have little response to the target ligand segment of choice. This is often the case primarily because the carrier segment tends to be the larger segment, usually 300 or more amino acids. In naturally occurring proteins used as carrier segments, there are also a large number of charged amino acids.

Charged amino acid sequences are more likely to be surface-exposed and antigenic than are hydrophobic amino acid sequences. Thus, the carrier segment has more potential epitopes, and consists of residues which frequently are more easily recognized as foreign or dangerous by the immune system. By making the carrier segment small and very low in antigenicity, the immune system will be more likely to attack the ligand and produce antibodies to the ligand.

For the purposes of the present invention, low antigenicity is defined as failure of the carrier segment to induce formation of greater than 50% of the specific antibody generated in response to three or more injections into chickens, mice and rabbits of a fusion protein consisting of the carrier segment fused to a ligand having the sequence: H<sub>2</sub>N-Lys Met Ala Glu Asp Asp Pro Tyr Leu Gly Arg Pro Glu Gln Met [SEQ. ID. 4].

One way of reducing the antigenicity of the carrier segment is to reduce its size. This allows the attached ligand to comprise a significantly greater fraction of the total fusion protein. Typically, the carrier segment contains between approximately 200 and 500 amino acids in

length. However, by reducing the length of the segment to an amino acid length of approximately 100 or fewer amino acids and removing many charged amino acids, the carrier segment is less effectively displayed to the immune response in the host organism. The carrier segment should be at least 65 amino acids long, and preferably 100 amino acids long. At the very least, the length of the carrier peptide should be sufficiently long to allow effective expression within the procaryotic host expression organism.

5  
10       **Low Solubility:** A major advantage of the present carrier segment is that it is sparingly or slowly soluble. This results in an advantage for rapid purification since injection quality immunogen containing low levels of pyrogen can be prepared using simple washes as opposed to  
15 conventional methods such as chromatography, thus resulting in savings in both time and equipment. Additionally, the sequestration of the peptides in inclusion bodies when expressed may protect labile sequences from proteolytic attack.

20       **No Need for Adjuvants:** An additional advantage of the carrier segment is that it may act as its own adjuvant as well as a conventional carrier protein due to various properties of the carrier segment and of conjugates containing the segment, including low solubility and  
25 mitogenic effects.

A typical way researchers currently prepare antigens for production of antibodies is to chemically synthesize the ligand or peptide using techniques known to the art, and then to chemically crosslink it to a larger protein, known as a carrier protein. The function of the carrier  
30 protein is to elicit T-cell help. T-cell help is important in producing an effective antibody response within an animal. However, many ligands and peptides are too small to both present the desired antigenic site and to include  
35 a segment which allows the material to elicit T-cell help. Certain proteins, such as keyhole limpet hemocyanin, are known to the art to contain effective sites for eliciting

T-cell help, and are thus often coupled to small ligands for this purpose. Unfortunately, as discussed previously, many of these also are antigenic and can dominate the antibody response. The carrier segment described elicits  
5 the necessary T-cell help without dominating the antibody response, and thus is a superior carrier protein.

A typical way researchers currently prepare a dosage of the antigen for injection for the production of antibodies is to formulate it in any number of suspension,  
10 precipitate or emulsion forms, called adjuvants. Adjuvants can augment the immune response as the result of the combined effect of several factors. If the antigen were injected into the host animal as is, it would be in a soluble form and would be quickly dispersed from the site  
15 of injection and cleared from the body. Since the immune system needs time to recruit immune cells to the site of injection and to mount a response, the quick dispersal and clearance of antigen is detrimental to the immune response. Formulation of the antigen so that it is trapped at the  
20 site of injection is an effort to keep the antigen localized long enough for the immune system to locate it and mount a response. In most cases, the antigen is not trapped long enough at the site to elicit a robust immune response, so multiple injections over a period of several  
25 weeks are required. Additionally, recruitment of immune cells to the site of injection usually requires some local nonspecific inflammation. For this reason, some adjuvant formulations also contain an irritant for this purpose. Adjuvants also may trap the recruited immune cells, thereby  
30 enhancing the interactions of the immune cells. Finally, adjuvants may stimulate proliferation of the immune cells.

The low solubility of the carrier segment and of conjugates containing it creates conditions at the injection site that are sufficient for mounting an immune  
35 response; namely, that some sort of nonspecific inflammatory response is created that recruits immune cells to the location, that antigen is sequestered at the site



long enough for an immune response to be mounted, that interactions between the immune cells may be potentiated, and that immune cell proliferation is stimulated. If the solubility were too low, or if the antigen were not accessible to the immune system, no response would be achieved; thus, the solubility of the carrier segment is thought to be in an optimal range which balances the need for sequestration against the requirement for slight solubility and effective antigen display. Thus, the carrier segment has been designed to provide all functions required for eliciting an immune response; recruitment of immune cells to the injection site, sequestration of antigen at the site, eliciting T-cell help without dominating the antibody response, and effective antigen display to the immune system. The advantages of this system over prior art is that it eliminates the need for a step involving coupling to a carrier protein, and a step involving formulation in an adjuvant. Additionally, a single injection of antigen is sufficient to elicit an ample immune response.

Most adjuvants induce the formation of granulomas in animals and humans. For this reason, most adjuvants are not allowed for use in humans although they are allowed for use in animals (Klein, 1990). Therefore, a system which does not require the use of adjuvants is not only more humane, but may have significant benefits specifically in the field of vaccine development.

Using the carrier segment described, antibody isotype response may be able to be altered. Different isotypes or classes of antibody heavy chains are known to have unequal effector functions, such as the capacity to fix complement, and unequal capacity to bind available affinity resins, such as Protein A. Thus, antibodies with the same antigen specificity but of a different isotype have disparate effector functions and resin-binding affinities. The system of the present invention induces different antibody isotype profiles in response to different concentrations of

the antigen. This suggests that a system may be developed which will allow the regulation of the predominant isotype or class of the antibodies which are made using this technology.

5       **Excellent Expression:** The property of excellent expression simplifies the production of a fusion protein by allowing small fermentations to be performed for the isolation of sufficient antigens for immunizations as well as subsequent uses such as validation assays and affinity  
10 purification regimens. It is logical to assume that enough of the fusion protein must be made in order for it to be injected into the host animal for antibody production. Usually, research requires the injection of more than one host animal. The carrier segment of the present invention  
15 is advantageous in that it is able to be expressed at a very high rate, e.g.,  $\geq 5$  mg/l in standard culture medium, in bacteria. Another advantage is that it allows the accumulation of the peptide without rapid degradation, thus allowing intact fusion proteins to be isolated.

20       **Works with a Variety of Target Ligands:** Another advantage of the carrier segment of the present invention is that it is relatively nonspecific in terms of attaching to target ligands. Therefore, virtually any type of ligand can be fused to the nonantigenic, sparingly soluble carrier  
25 segment to produce a useful immunogen in which the carrier segment is nonantigenic and the desired peptide is selectively displayed to the immune system.

30       **Broad Utility as an Antigen:** Another advantage of the present invention is that the fusion protein created by the carrier segment of the present invention creates enhanced antigenic responses in most antibody producing species. Typical species include vertebrates such as the mouse, rat, rabbit, chicken, goat, sheep, donkey, horse and human. The fusion protein has been shown to be effective using a  
35 variety of routes of injection as discussed *infra*.

**Yield of Specific Antibodies Can be High:** Another advantage of the present invention is that the ratio of

specific antibodies to the ligand of interest compared to those antibodies directed against the carrier segment of the fusion conjugate is high. Typical carriers, such as KLH or BSA, are both antigenic in nature and much larger in size than the ligand. Thus, many or most of the antibodies produced in response to immunization with such a compound are directed against the carrier segment.

The present invention constitutes a much smaller carrier segment which has low antigenicity. Since there are both fewer epitopes and less antigenic epitopes presented to the immune system with the current invention, there is a net effect of making the ligand immunodominant. This results in a more robust immune response to the ligand of interest.

**Production of Peptides:** The present invention also advantageously allows the rapid production of large quantities of short peptides of defined sequences to be expressed as an insoluble fusion protein. The hydrophobic carrier segment can be cleaved and removed, or left attached. In addition to the uses listed above, leaving the carrier segment attached enables the peptide to be immobilized on hydrophobic surfaces, which may have utility for a wide variety of applications. The peptides can be used in all ways other short peptides are used, such as the neutralization of antibodies, direct immunization as discussed above, conjugation to other carriers for immunization, epitope mapping, as therapeutic agents, substrates for the assays of enzymes, and other applications. As is well-known in the prior art, fusion proteins can be processed by a variety of reagents to yield the desired peptide sequence separated from the carrier segment. An advantage of this invention is that removal of the carrier segment is facilitated by the low solubility of the carrier segment when the desired peptide is cleaved off.

Other advantages of the present invention over conventional peptide synthesis include lower cost of

production of small quantities of peptides of defined sequences. Further, no toxic reagents are required in the process of the present invention. There also is less of a chance of modification of amino acid side chains, which has  
5 been demonstrated to be a problem with conventionally synthesized peptides.

The present invention also offers significant improvements over the current technology for making antibodies to peptides or proteins. The present invention  
10 makes it easier for an antibody to be made from a peptide sequence of a protein without requiring knowledge of the entire sequence of the target protein, as well as making antibodies with high affinity, specificity, and avidity to both the peptide and the parent protein from which the  
15 peptide was derived. Therefore, the basic problems involved with immunization, immunoaffinity purification of antibodies from polyclonal sera, peptide production and epitope mapping or identification can all be accomplished in facile, inexpensive, safe ways using equipment and  
20 methods very familiar to biologists not accustomed to working with peptides or synthesizing peptides.

The product of the present invention is designed to 1) produce a safe vaccine against infectious diseases, and 2) synthesize defined proteins against which antibodies can be  
25 raised for experimental, industrial, pharmaceutical and diagnostic purposes.

The present invention also is useful in the production of diagnostic reagents for use in diagnostic assays. The fusion protein, comprising the combination of carrier  
30 sequence and ligand, can be dispersed or immobilized on a variety of solid supports such as test tubes, microliter plate wells, dipsticks and the like. Moreover, using this technology makes it possible to generate longer peptides than feasible under standard chemical synthetic methods.

35 These and other aspects of the present invention will become evident upon reference to the following detailed

description of the invention, the examples, and the attached drawings and photographs.

#### BRIEF DESCRIPTION OF THE DRAWINGS

5        Fig. 1 is an amino acid sequence of the preferred carrier protein [SEQ. ID. 1] of the present invention.

      Fig. 2 is the preferred amino acid sequence of the polylinker segment [SEQ. ID. 3] of the present invention.

10       Fig. 3. is the amino acid sequence of the combined carrier segment and polylinker segment [SEQ. ID. 2] of the present invention.

      Fig. 4 is a flow chart illustrating the production and use of the fusion protein of the present invention.

15       Fig. 5A is a graph illustrating purity assessments of fusion proteins purified by the method of the present invention as assessed by reversed-phase HPLC, and fast-atom bombardment mass spectrometry as described in Example 3. In Fig. 5A, a purified fusion protein containing the carrier segment was assayed by high pressure liquid  
20       chromatography (HPLC). The desired protein peak is indicated by an arrow. The peak due to acetic acid adsorption is indicated with an open circle.

      Fig. 5B is a graph illustrating purity assessments of fusion proteins purified by the method of the present  
25       invention as assessed by reversed-phase HPLC, and fast-atom bombardment mass spectrometry as described in Example 3.

      Fig. 5B is specifically a mass spectrogram of fusion protein purified from pMK160. As noted on Fig. 5B, the mass of the M+1 peak is extremely close to that predicted  
30       from the cDNA sequence.

      Fig. 6 is a diagram illustrating the immobilization of carrier protein conjugates on solid surfaces in Example 4.

      Fig. 7 is a graph illustrating the antigenic response of mice to a fusion protein made between the carrier  
35       protein of the present invention and a peptide segment derived from p50 and demonstrating the predominant antibody

response is directed against the ligand, not the carrier segment, in Example 5.

Fig. 8 is a graph illustrating the antibody titers from mice immunized with 1 mg/ml fusion peptide in the presence of Freund's adjuvant (complete at the primary and incomplete with each boost) and tested using different adjuvants in Example 6.

Fig. 9A is a graph illustrating the antibody titers from mice immunized with 2 mg/ml - 0.1 mg/ml fusion peptide in the presence of adjuvant in Example 7.

Fig. 9B is a graph illustrating the antibody titers from mice immunized with 2 mg/ml - 0.1 mg/ml fusion peptide in the absence of adjuvant in Example 7.

Fig. 10 is a graph illustrating the capacity of the system of the present invention to induce significant antibody response with a single injection as described in Example 8.

Fig. 11A is a graph illustrating the production of polyclonal antibodies in mice using the system of the present invention with immunization of mice in Example 9.

Fig. 11B is a graph illustrating the production of polyclonal antibodies in rabbits using the system of the present invention with immunization of mice in Example 9.

Fig. 11C is a graph illustrating the production of polyclonal antibodies in chickens using the system of the present invention with immunization of mice in Example 9.

Fig. 12 is a graph illustrating the capacity of polyclonal antibodies made using the system of the present invention to bind peptides and full length target proteins in Example 10.

Fig. 13 is a graph illustrating the production of high proportions of peptide-specific polyclonal antibodies and peptide-specific, soft-release polyclonal antibodies in Example 11.

Fig. 14 is a graph illustrating the proliferative effects of the carrier segment on splenocytes from nonimmunized mice in Example 12.

DETAILED DESCRIPTION OF THE INVENTIONDefinitions

The following definitions are provided to assist in providing a clear and consistent understanding of the scope and detail of the terms:

**Adjuvant:** A substance that nonspecifically augments the immune response to an antigen when mixed with the antigen prior to injection, or when injected separately but into the same site. Adjuvants are generally classified into five groups: oil adjuvants, mineral salts, synthetic polymers, liposomes, and natural substances.

**Amino Acids:** Amino acids are shown either by three letter or one letter abbreviations as follows:

	<u>Abbreviated Designation</u>	<u>Amino Acid</u>
15	A Ala	Alanine
	C Cys	Cysteine
	D Asp	Aspartic acid
	E Glu	Glutamic acid
	F Phe	Phenylalanine
20	G Gly	Glycine
	H His	Histidine
	I Ile	Isoleucine
	K Lys	Lysine
	L Leu	Leucine
25	M Met	Methionine
	N Asn	Asparagine
	P Pro	Proline
	Q Gln	Glutamine
	R Arg	Arginine
30	S Ser	Serine
	T Thr	Threonine
	V Val	Valine
	W Trp	Tryptophan
35	Y Tyr	Tyrosine

**Antigen:** A substance recognized by T- and B-cell receptors and which activates lymphocytes by interacting with the combining sites of T- or B-cell receptors.

**Avidity:** The overall tendency of antibodies to combine with antigens. Avidity is influenced by affinity, valency of antigens and antibodies, and the composition of antibodies.

**Biological Activity:** The capacity of acting or reacting in some specific way in a biological system.

**Carrier Segment:** A protein which allows coexpression of a heterologous peptide as a normal extension of or insertion in the polypeptide chain to form a fusion protein defined below, and/or which may be chemically coupled to a peptide, hapten, or other ligand to form a carrier protein conjugate defined below, and/or which may be coadministered with an antigen as described under "coadministration." The carrier protein will generally have a molecular weight between about 10 to 50kDa and preferably will not have an accessible internal cleavage site. The DNA and amino acid sequence of the preferred carrier protein is shown in Fig. 1 [SEQ. ID. 1].

**Cloning Vehicle:** A plasmid, phage DNA, cosmid or other DNA sequence which is able to replicate in a host cell, characterized by one, or a small number of, endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production of coat proteins or loss of promoter or binding sites, and which contain a marker suitable for use in the identification of transformed cells, e.g., tetracycline resistance or ampicillin resistance. A cloning vehicle is often called a vector.

**Coadministration:** Mixing a desired antigen with a finely divided or soluble portion of the carrier segment, resulting in the physical entrapment of or association of the antigen with the carrier segment, followed by injection of the mixture into a host organism. Upon injection of the mixture, the antigen is considered to be coadministered. Alternatively, consecutive injections of the carrier and antigen into the same site may be considered coadministration.

**Carrier Protein Complex:** A preparation which consists of a carrier segment and a peptide, hapten, or other ligand, wherein the association between the two is noncovalent in nature. This includes physical entrapment



of one by the other, electrostatic, hydrophobic, or affinity interactions, and chelates.

**Carrier Protein Conjugate:** A molecule which consists of a carrier segment and a peptide, hapten or other ligand, wherein the association between the two is any sort of covalent chemical bond. Such a molecule would typically be produced using a chemical crosslinking reagent. A subset of the carrier protein conjugate is a fusion protein as described below.

**DNA Sequence:** A linear array of nucleotides connected one to the other by phosphodiester bonds between the 3' and 5' carbons of adjacent pentoses.

**Epitope:** A small region of the ligand's surface that binds with the antibody. Epitopes also serve as antigenic determinants.

**Expression:** The process by which a polypeptide is produced by a gene or DNA sequence. It is a combination of transcription and translation. As it relates to proteins, expression refers to the directed synthesis of large amounts of desired proteins. Overexpression refers to production of a desired protein in amounts exceeding that normally produced by the cell in question.

**Fusion Protein:** A class of carrier protein conjugates which consists of a carrier segment and a chosen peptide, in which the connection between the two is a normal extension of or insertion in the polypeptide chain. A fusion protein could be produced by expression of a gene encoding the fusion sequence or by chemical coupling of the two in such a manner that a normal peptide linkage is formed.

**Hapten:** A substance of low molecular mass (typically lower than 4000 daltons) that can bind antibodies and induce immune response if covalently attached to a large carrier molecule.

**Heterologous Peptide:** A peptide which is not endogenous to the host selected, although this definition also includes endogenous peptides in cases in which

overexpression of such is desired. Heterologous peptides are short relative to most proteins, generally having a molecular weight of less than about 10kDa, and may be glycosylated, sialylated, phosphorylated, or the like. The peptide also will exhibit some form of useful activity, typically either biological activity, e.g., as a peptide hormone, or antigenic activity for use in recombinant vaccines and/or immunological assays. The peptide may either omit any cleavage site or may express a site in an inaccessible portion of the peptide, e.g., at a position of the peptide which is masked by another portion of the peptide, or by glycosylation, phosphorylation, or the like.

**Immunogen:** A substance capable of eliciting immune response.

**Immunological Binding Activity:** The specific capacity to bind to an antibody.

**Inclusion Body:** An inclusion body protein is one overexpressed in the host which at some stage of expression or purification is visible by phase contrast microscopy as a precipitate, regardless of the physical state of the protein at the time it is referenced. A further description of inclusion body can be found in U. S. Patent 4,512,922 to Jones et al., which is incorporated herein by reference for a description of inclusion bodies, and which refers to inclusion bodies as "refractile bodies."

**Isotypes:** Classes or subclasses of antibody defined by shared epitopes present on all molecules of the heavy chains in that antibody class or subclass in a given animal species, e. g., IgM, IgG<sub>1</sub>, and IgG<sub>3</sub>.

**Ligand:** A molecule that binds a specific receptor or enzyme. Examples include proteins, peptides, haptens, polysaccharides or other biomolecular entities, and are known to interact with antibodies.

**Nucleotide:** A monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (1' carbon of the pentose) and

that combination of base and sugar is called a nucleoside. The base characterizes the nucleotide. The four DNA bases are adenine (A), guanine (G), cytosine (C), and thymine (T). The four RNA bases are A, G, C, and uracil (U).

5       **Nucleotide Base Sequence:** A linear array of nucleotides in a DNA molecule commonly prepared from four dNTP precursors: dATP, dCTP, dGTP and dTTP. Modified bases, other than the usual four found in DNA, also may be incorporated.

10       **Peptide:** A compound consisting of 2-50 naturally occurring or synthetic amino acids which also can be further modified, as described above, which is covalently linked through peptide bonds formed from the  $\alpha$ -carboxyl group of one amino acid and the  $\alpha$ -amino group of the next  
15 amino acid by elimination of a molecule of water. The amino acids can be either naturally occurring amino acids as described above, chemically synthesized variants of such amino acids such as norleucine, or modified forms of these amino acids which can be altered from their basic chemical  
20 structure by addition of other chemical groups which can be found to be covalently attached to them in naturally occurring compounds. Some of the modifications so attached include: phosphate groups, lipid groups, nucleotide groups, and polymers of sugars and will include other  
25 modifications known to those skilled in the art.

**Plasmid:** A nonchromosomal, double-stranded DNA sequence comprising an intact "replicon" such that the plasmid is replicated in a host cell. When the plasmid is placed within a unicellular organism, the characteristics  
30 of that organism may be changed or transformed as a result of the DNA of the plasmid. For example, a plasmid carrying the gene for tetracycline resistance (TETR) transforms a cell previously sensitive to tetracycline into one which is resistant to it. A cell transformed by a plasmid is called  
35 a "transformant."

**Recombinant DNA Molecule or Hybrid DNA:** A molecule consisting of segments of DNA from different sources which

have been joined end-to-end outside of living cells and are able to be maintained in living cells.

#### BASIC INVENTION

5       The basic invention is directed to the construction of a carrier protein conjugate or a carrier protein complex. The carrier protein conjugate or complex comprises a first amino acid sequence, wherein the first amino acid sequence is substantially non-naturally occurring and insoluble, and  
10       a ligand having biological activity or immunological binding activity.

#### CARRIER SEGMENT

##### Properties of Carrier Segment

15       The present invention is specifically directed to a proteinaceous carrier segment which will be referred to as a "carrier segment" or "the segment." The carrier segment described in this invention has free amino and carboxy termini, although that is not necessary for most of the  
20       purposes described. The carrier segment has been designed to have several properties that are of importance to the present invention. The carrier segment is hydrophobic. Since the carrier segment dominates the solubility behavior when attached to short peptides and ligands, conjugates  
25       containing it are sparingly soluble in neutral aqueous solutions.

      The carrier segment and fusion proteins containing it are expressed to high levels in *E. coli* and are made as insoluble protein granules known as inclusion bodies. The  
30       protein found in these inclusion bodies is easy to purify in large quantities using techniques known to the art. The carrier segment itself has low antigenicity when injected into animals, but will adequately display an attached ligand to the immune system of an animal. The carrier  
35       segment also lacks many sites of cleavage recognized by proteases with specificity for a single amino acid, and is

soluble in some solutions that allow cleavage by chemicals and enzymes, e.g., urea, SDS, formic acid, and formamide.

#### Design of Carrier Segment

5       A carrier segment with the above favorable properties was designed in several defined steps. By using these steps and one extra step not needed in this case, a researcher could design other carrier segments starting with different proteins. A highly expressed protein  
10       sequence was identified for which an expression vector was available (in this case gene 10 protein of phage T7, encoded by vector pGEMEX-1).

      The initial protein in this case was expressed at about 100 mg/l of culture in *E. coli* cells. Next, the  
15       designed protein sequence was truncated to 79 amino acids, not counting the polylinker amino acids as described later. Making the sequence smaller, it is less likely to contain antigenic sites to start with. There appears to be a length minimum at around 65 amino acids below which good  
20       expression is not obtained in *E. coli*.

      The truncated sequence was further modified by substituting uncharged amino acids or histidine for the charged amino acids lysine, arginine, aspartic acid, and glutamic acid. Any tryptophan or cysteine residues were  
25       changed to any uncharged amino acid, and all methionines, except for the amino terminal one (necessary if expression were to be accomplished in *E. coli*), were substituted with any uncharged amino acid, most often valine. In general, a replacement amino acid was selected which did not require  
30       great changes in the DNA sequence of the expression vector; usually only the third base of the codon was changed. Other slight changes (1 amino acid insertions) in amino acid sequence were made to accommodate cloning of the DNA encoding the carrier segment into the expression vector,  
35       described later.

      Thus, the salient design feature of the carrier segment is that it is truncated to about 79 amino acids,

not counting the polylinker amino acids as described later, and lacks at least two and preferably all of the following list of amino acids: glutamic acid, aspartic acid, lysine, arginine, methionine (except for the single methionine placed on the amino terminus of the segment which is required for translation initiation in *E.coli*), tryptophan, and cysteine. The lack of these amino acids is accomplished by substituting uncharged amino acids. If the starting protein were very hydrophilic and especially if it contained many uncharged hydrophilic amino acids such as threonine and serine, following the above design rules might not result in a protein that was hydrophobic enough to have the desired low solubility. In this case, a further design rule would be to systematically substitute hydrophilic amino acids with more hydrophobic ones such as leucine, isoleucine, valine, and alanine, until the desired low solubility was achieved.

Not all of the charged amino acids must be eliminated. In some cases, it is desirable or necessary to leave one or more charged amino acids in the carrier segment. For example, in order to clone a peptide-encoding DNA sequence into the expression vector for the carrier segment, the vector must contain some sites where restriction enzymes can cut. Usually several such sites are clustered in a single locus in the vector, creating what is commonly called a polylinker. There are often a few charged amino acids encoded by the DNA sequence in such polylinker sequences. Thus, the ideal carrier segment is devoid of charged amino acids except at the polylinker site.

As stated above, it is desired to create a carrier segment having only enough size to accomplish the desired purpose. Suitable carrier segments have been produced which have a length between about 65 and 100 amino acids long.

The preferred amino acid sequence of the carrier segment consists of 79 amino acids [SEQ. ID. # 1] and is illustrated in Fig. 1. The amino acid sequence of the

carrier segment also can include a polylinker segment (Fig. 2 [SEQ. ID. 3]) and thus be a combination of the carrier segment of Fig. 1 and the polylinker segment of Fig. 2, as illustrated in Fig. 3 [SEQ. ID. 2.].

5

#### **Direct Use of Carrier Segment Described Above**

As described later, a researcher will wish to modify the DNA vector encoding the carrier segment to include polylinker segments or fused peptide sequence of interest.

10 The carrier segment also can be produced without further amino acids being added or modified and advantageously used in several ways as described below.

**As Part of a Carrier Protein Conjugate:** The carrier segment can be fused to a second chemical entity or ligand.

15 As described later, this conjugate can be made by chemically coupling a ligand to the purified carrier segment. The conjugates thus prepared may be used for immunizations, coating of surfaces, receptor binding, and many of the other ways described elsewhere in this invention.

20 **As an Adjuvant:** The carrier segment also has use as an adjuvant, i. e., without necessarily being fused to a ligand. The carrier segment can be coadministered with a protein for injection into a host animal. Typically, the carrier segment will work best with high molecular weight proteins or other polymers and biopolymers. Preferably, the molecular weight of the coadministered molecule is at least about 4,000 daltons.

25 The carrier segment is mixed with the desired molecule and coinjected into animals. This is advantageous in that the carrier segment nonspecifically augments the specific immune response to the desired molecule, resulting in the generation of a stronger immune response of the animal to the desired molecule. This property, along with others, indicates that the carrier segment demonstrates activities which define it as an adjuvant.

30  
35

**LIGAND**

The ligand can be a second peptide segment, a nonpeptide chemical moiety or hapten, or a mixed composition consisting of both a peptide segment chemically  
5 linked to a nonpeptide chemical entity.

Examples of chemical moieties which are available for fusion to the carrier segment include fluorescent moieties such as rhodamine, fluorescein, dansyl, and derivatives of such compounds; mono and polysaccharides; pharmaceutical  
10 agents; and derivatives and metabolites of such agents; environmentally hazardous chemicals and derivatives and metabolites of such agents, pesticide chemicals and derivatives and metabolites of such agents, and lipids.

The chemical moieties are chemically attached to the carrier segment by a variety of means discussed in more  
15 detail later. Such means would include use of pre-derivatized compounds designed to couple the desired moieties to biomolecules, use of chemical crosslinking agents, or expression as a fusion protein if the ligand is a peptide segment. A wide range of reagents for coupling  
20 ligands to biomolecules are commercially available from corporations such as Molecular Probes (Eugene, OR) and Pierce Chemical (Rockford, IL). Some of these reagents also allow for the coupling of multiple copies of the  
25 ligand to the carrier segment.

The ligand may have either immunological binding activity (otherwise known as "immunologically active") or other biological activity. The ligand may have a single activity, for example antigenicity, receptor binding  
30 activity, therapeutic activity, or targeting activity, i.e., the ability to move to a given locus in a host animal after administration. The ligand also may have a combination of two or more such activities.

If the ligand is a peptide, it may be an amino acid sequence known to the art or yet to be developed or  
35 identified. Examples of the amino acid sequence include derivations from a lymphokine gene such as an interferon



gene or a gene coding for an antigen of an infectious agent such as a virus, bacterium or other parasite. For example, it may be an antigen of influenza virus, an HIV virus, a rabies virus, etc. It also may be a fragment of the above  
5 antigens or a peptide resulting from a chemically synthesized coding sequence such that the resulting peptide has substantially the same antigenicity as the above antigens or fragments thereof. Reference is made to U.S. Patent 5,008,373 to *Kingsman et al.*, which is incorporated  
10 herein by reference for a disclosure of examples of suitable amino acid sequences.

#### EXPRESSION VECTOR

Referring to Fig. 4, the production of various  
15 proteins of interest is achieved by expressing in host cells a proteinaceous carrier segment A or carrier segment-containing fusion protein A + B, which is then collected and purified, and then either used directly, linked to a ligand B, coadministered with a ligand B", or cleaved to  
20 remove the carrier segment B'.

The process involves the engineering of a recombinant DNA vector which, upon transformation into a suitable host, and subsequent expression, produces the carrier segment or carrier segment-containing fusion protein in abundance.  
25 Although the preferred host cells are procaryotic cells such as *E. coli*, the invention also includes production of carrier segments or carrier segment-containing fusion proteins in a variety of host cells; for example, yeast cells such as *S. cerevisiae*, animal cells such as Chinese hamster ovary (CHO) cells, or COS cells containing a  
30 suitable expression vector that directs production of the desired protein.

Construction of suitable vectors and cassettes containing the desired coding and control regions employs  
35 DNA manipulations (oligonucleotide synthesis, ligation, restriction) which are well understood in the art. Isolated plasmids, DNA sequences, or synthesized

oligonucleotides are cleaved, tailored, and relegated in the form desired.

A prot in-coding cassette is constructed which encodes the desired carrier segment. The protein encoded by the cassette is about 10 kilodalton (10 kD) in molecular weight, and holds to the design principles of the carrier segment described above; namely, in brief that it has low solubility and antigenicity due to the selective removal of many charged amino acids. The preferred carrier segment protein and DNA sequence is illustrated in Fig. 1 [SEQ. ID. 1].

The protein-coding cassette for the above-designed carrier segment is then subcloned into a suitable expression vector. Usually this is a plasmid vector, although other systems could be used depending on the host organism used for expression. In the examples presented, the expression vector is a modification of a vector known as pGEMEX-1, which is described in Promega Corporation's (Madison, WI) catalog. The plasmid vector is a derivative of the well-known pBR322 vector derived from an *E. coli* species by Bolivar et al (1977). Expression of the carrier segment protein is driven by a promoter for T7 RNA polymerase. Other plasmids which contain replication sites, control sequences, and antibiotic resistant markers derived from a species compatible with the host also could be used. Commonly used prokaryotic control sequences which are defined herein include promoters for transcription initiation and termination along with ribosome binding site sequences, and include such promoters as the beta-lactamase promoter.

The expression systems useful in eukaryotic systems of the invention comprise promoters derived from appropriate eukaryotic genes. A class of promoters useful in yeast, for example, include promoters for synthesis of glycolytic enzymes, including those for 3-phosphoglycerate kinase.

Even more advantageous to the present invention is the use of an expression vector construct which contains the

DNA encoding the carrier segment and which has this segment followed by a nucleotide segment, called a polylinker segment (C in Fig. 4), which contains the recognition sequence of at least one restriction endonuclease enzyme and which does not contain translation termination codons within the known reading frame of the carrier segment and the DNA encoding the restriction endonuclease site. Such a polylinker segment is advantageous in that the DNA encoding the expression vector can then be cut at specific sites in the polylinker using the restriction endonuclease, and a DNA segment encoding a desired peptide ligand can be inserted into the expression vector at this point. In such a situation, one must ensure that the resulting vector will encode for a fusion protein containing the carrier segment and peptide of interest, that there will be no translation termination codons in the reading frame in the intervening DNA between the DNAs encoding the carrier segment and the ligand, and that the inserted DNA should include a translation termination codon at the end of the desired fusion protein. The knowledge concerning the proper design and use of polylinkers in the production of fusion proteins is well-known in the art. If desired, confirmation of the amino acid sequence of the resulting construct can be done by determining the DNA sequence of the resulting vector by use of methods well-known in the art.

The preferred DNA sequence of the polylinker and the amino acids encoded by the polylinker sequence is illustrated in Fig. 2 [SEQ. ID. 3]. As discussed earlier, some of the codons in the polylinker segment encode charged amino acids. This is not detrimental to the performance of the fusion protein.

The preferred DNA sequence of the complete vector plus the polylinker consists of the sequence shown in Fig. 3 [SEQ. ID. 2], wherein the remainder of the vector comprises pGEMEX-1, in which the DNA sequence from 5 to 905 are replaced with the sequence described in Fig. 3 in such a manner that the ATG codon (Met) is proximal to the T7

promoter sequence in the pGEMEX-1 vector. Note that when peptide-encoding oligonucleotides are cloned into the polylinker with a translation terminator at the end of the desired peptide, some of the amino acids on the carboxy terminal end of the sequence of Fig. 3 will not be present in the fusion protein. When fusion peptides are produced by cloning into the Not1/Hind3 site described in Example 2, the C-terminal 8 amino acids are missing. This does not adversely affect the properties of the fusion proteins.

#### EXPRESSION STRAIN

The proteins of the invention may be expressed in either prokaryotic or eukaryotic systems. Prokaryotes are most frequently represented by various strains of *E. coli*. The preferred host strain is BL21(DE3) plysS, a strain commercially available from Novagen Corporation (Madison, WI). However, other microbial strains also may be used, such as bacilli (for example, *B. subtilis*), various strains of *Pseudomonas*, and others. Common eukaryotic expression strains would include strains of yeast, and baculovirus expression in insect cells. One possible advantage of the invention is that the deposition of the expressed protein in insoluble deposits may allow expression of fusion proteins that might otherwise be more detrimental or toxic to the cell.

#### Transformation

Depending on the host cell used, transformation is accomplished using standard techniques appropriate to such cells. The calcium chloride treatment, such as described by Cohen (1972) or the RbCl method described in Maniatis et al. (1989) is used with prokaryotes which contain substantial cell wall barriers. The preferred host strain is BL21(DE3) plysS, and the transformation protocol used is the one recommended by the manufacturer (Novagen Corp., Madison, WI).

### Verification of Construction

After transformation, successful transformants are selected by ampicillin (preferred), tetracycline, or other antibiotic resistance or using other markers depending on the plasmid construction as is understood in the art. Plasmids from the transformants are then prepared according to the method of Clewell et al. (1969). The sequence of the plasmid can then be verified by standard DNA sequencing methods well-known to the art.

### PRODUCTION AND PURIFICATION OF CARRIER SEGMENT AND FUSION PROTEINS

#### Expression/Cell Harvest

Transformed expression strains are grown in shake flasks or fermentors to a suitable density. Then, expression of the desired protein is stimulated using the appropriate induction protocol. In the preferred case, the induction is accomplished by the addition of isopropyl-B-thiogalactopyranoside (IPTG), a standard inducer for T7 expression strains. In some cases, addition of agents such as rifampicin, which block the action of the host RNA polymerase, may cause an increase in production of the desired protein. Alternatively, an expression system may be used in which the expression is unregulated. The time for harvest of cells can either be predetermined, or checked by monitoring protein expression in real time.

Expressing cells can be harvested by centrifugation and stored up to several weeks at -70° C before breaking them and purifying the protein contained therein.

#### Purification of Carrier Segment and/or Fusion Proteins

Since the expressed protein is in general much less soluble than the other proteins in the cell, it is relatively easy to purify from prokaryotic cells using standard techniques known in the art. First, the cells are lysed by enzymatic or mechanical means in a buffer. The preferred method is sonication, although any other lysis

method will work, as long as lysis is complete and DNA and RNA are sufficiently fragmented so as not to pellet upon centrifugation. Preferred buffers contain Tris buffer at pH 7-8, isotonic saline, and dithiothreitol (DTT) to maintain all cell proteins in a reduced state. After sonication, detergent is added to the mixture to solubilize most lipids and proteins, and the mixture is centrifuged; it is preferred to use a centrifuge speed of greater than 10,000G for 10 minutes. The desired protein is then found in the pellet fraction at a high degree of purity.

Higher purity is usually obtained by washing the pellet in a second wash solution, often containing a different agent or detergent. Washing is accomplished by resuspending the pellet in the fresh buffer followed by centrifugation as above. The preferred first detergent is sodium deoxycholate (NaDOC), and the second preferred detergent is Triton X-100.

After the detergent washes, the pellet can be washed either with the above buffer or with phosphate-buffered saline (PBS) to remove trace detergent, then resuspended in a volume of a desired buffer for storage or use in any of the ways described elsewhere, including immunization. The advantage of the low solubility of the protein is that the purification is easy and quick, and requires very little specialized equipment.

The proteins purified by the above method are ready for use in any or all of the applications contemplated in the invention, including but not limited to the following; immunization of animals, use as an adjuvant, coupling to other ligands, use as a protease inhibitor, immobilization on hydrophobic surfaces, use as an enzyme substrate, and use in peptide production after cleavage.

#### 35 PRODUCTION OF CARRIER PROTEIN CONJUGATES FROM PURIFIED CARRIER SEGMENTS AND DESIRED LIGANDS

The purified carrier segment either can be used directly for the applications described under "carrier

segment", or it can be derivatized with a variety of ligands described under "ligand" using the strategies described below. These include the use of prederivatized ligands, chemical coupling reagents, and crosslinking reagents.

#### Use of Prederivatized Ligands

In many cases, the linkage of the desired ligands to the carrier segment can be accomplished by use of commercial derivatives of such compounds which have been produced to facilitate the addition of such compounds to molecules, such as fluorescein isothiocyanate, NHS-Rhodamine (Pierce Chemical Co., Rockford, IL, Products 46110 and 46102, respectively.), and Sulforhodamine 101 acid chloride (Aldrich Chemical Co., Milwaukee, WI, Product 28,406-8). Many of these compounds have been specifically synthesized so that they react with the chemical groups which are found in proteins, such as the amino-terminus, carboxy-terminus, the hydroxyl functions of the amino acids serine and threonine, in such a way as to covalently attach the desired chemical moiety to the protein. The catalogs of many corporations such as Molecular Probes (Eugene, OR) or Pierce Chemical Co. (Rockford, IL) have a plethora of such compounds with known reactivities that can be used in many ways to selectively add such compounds to the carrier protein.

One advantage of the carrier segment in this regard is that since many reactive amino acid side chains are not present, one can obtain a more selective localization of the site of ligand addition.

#### Use of Chemical Coupling Reagents

Another method for the formation of a carrier protein conjugate is to incubate the carrier segment and the ligand in solution with chemical entities which can facilitate the chemical coupling of the two segments without being included in the final product. One such method would be

through the use of reagents which couple a free carboxylic acid moiety to an amino group. The carrier segment described in this invention has a free amino terminus and carboxy terminus, and thus can be linked to a ligand or peptide through the use of such reagents if the ligand contains either a free carboxylic acid group or amino group somewhere in its chemical structure. One such reagent which is commonly used to form such linkages is 1,3 dicyclohexylcarbodiimide (DCC) (Aldrich Chemical Co., Milwaukee, WI, Product D8,000-2). When DCC is used in such a coupling reaction, an amide bond between the carrier segment and ligand is formed comprising the original carboxyl group and the amino group, with a concomitant expulsion of a water molecule. Thus, the final conjugate does not retain any part of the DCC reagent that was used to create the conjugate. Several different reagents having similar properties have been extensively described in the literature.

#### 20 Use of Crosslinking Reagents

Another method for the formation of a carrier protein conjugate is to incubate the carrier segment and the ligand in solution with chemical entities which can facilitate the chemical coupling of the two segments and are included in the final product to various degrees. The scientific interest in the use of such compounds has resulted in the development of many different reagents which provide different reactivities and advantages to the user and allow the user to select the particular reagent which will be most advantageous for their particular application. Reference is herein made to Tae, H. J., et al., (1983) for a description of the composition and use of many such reagents.

Such reagents are also widely commercially available through such suppliers as Aldrich Chemical Co., Milwaukee, WI and Pierce Chemical Co., Rockford, IL. Examples of such reagents include dimethylsuberimide (DMS) and m-



maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) (Pierce Chemical Co., Rockford, IL, Products 20668 and 22310, respectively).

5 If multiple copies of some chemical entity attached to the carrier segment are desired, but not by attaching the chemical moiety to chemical groups which are present in multiple copies within the sequence of the carrier segment, the user can form such a multiple derivatized carrier segment in several way. One way this can be done would be  
10 through the attachment of a peptide segment to the carrier segment which has multiple chemical groups which could be used for the formation of chemical crosslinks of the types described above. For example, a peptide sequence having three or more lysine residues in a short peptide sequence  
15 could be attached to the carrier segment. The new fusion made above could then be crosslinked to the chemical moiety of interest using these three new primary amino groups in the structure of the new fusion material and chemical entities which crosslink materials to amino groups.

20

#### **Uses of Conjugates Other than Immunization**

In addition to producing a material which could be used to generate antibodies to these chemical moieties, there are other advantages to coupling such materials to  
25 the carrier protein. Many of these materials are difficult to bind to particular materials, such as the plastics which are used to manufacture microtiter plate wells. The inability to bind such ligands to these materials in a way that allows them to be specifically bound by antibodies  
30 complicates their measurement using techniques such as ELISA testing. However, the carrier protein conjugates containing such ligands can be readily bound to such materials in such a way that the recognition of the chemical moiety by an antibody or enzyme is not inhibited.  
35 Thus, the ease of formation of such conjugates and the ability of such conjugates to present the ligands to antibodies and enzymes allow applications for the

chemically coupled carrier protein conjugates beyond their use as immunogens.

5                   **USE OF CARRIER SEGMENT-CONTAINING FUSION PROTEINS  
                    FOR THE PRODUCTION OF PEPTIDES**

          The present invention also is directed to the production and purification of biologically or immunologically active peptides using the fusion protein  
10       produced by the combination of the carrier segment and the desired peptide. This part of the invention basically relies on the combination of the carrier segment and the peptide with an intervening, cleavable amino acid sequence, which allows for the liberation of the peptide from the  
15       carrier segment using reagents which can sequence-specifically cleave protein sequences at peptide bonds. The desired peptide can then be easily separated, for example, by filtration or centrifugation, from the carrier segment, which is largely insoluble in aqueous solutions.  
20       Thus, there is provided a method producing a substantially pure and active peptide as described in the present invention. Unless otherwise described, the term "active" used alone is intended to mean either (or both) biologically active or immunologically active.

25       The carrier segment of the present invention provides the user with two important advantages: 1) it does not contain several of the common amino acids that can be attacked by sequence-specific reagents to cleave protein segments; and 2) the low solubility of the carrier segment  
30       allows the separation of the carrier segment from the released peptide to be easily accomplished in many instances. For example, if such a fusion is made which has the peptide fused to the end of the carrier segment, and the desired peptide does not contain any lysine residues,  
35       then a fusion protein can be expressed with a single lysine at the junction of the carrier segment and the desired peptide. The resulting fusion protein can be purified as described above, and then digested using proteases well-

known in the art, such as trypsin or endoprotease Lys C to cleave the fusion protein at the carboxy side of the lysine. This cleavage reaction would yield two product peptides; one would consist of the insoluble carrier segment with a lysine at its carboxy terminus, and the other would consist of the desired peptide, which in most cases will have considerable greater solubility in aqueous solutions.

10 **Vector Construction**

The fusion protein is created by methods discussed in the previous section, with the added design principle that the user designs the oligonucleotide encoding the new portion of the fusion protein so that an amino acid is present at the junction between the fusion protein and the peptide of interest that is lacking in both the carrier segment and the desired peptide. The amino acids designed to be absent from the carrier segment described earlier are methionine (except for the amino terminal met), lysine, arginine, tryptophan, glutamic acid, aspartic acid, and cysteine. Since reagents are available for cleavage of protein sequences at each of the amino acids missing in the carrier segment, this allows the user the luxury of choosing which of several amino acids they wish to place at the cleavage site in many cases. It is very desirable to use one of the amino acids that is not present in either the peptide or the carrier segment, so that only two products of the reaction are possible.

30 **Expression/Purification**

This would be accomplished using means described above.

**Digestion of Fusion Protein**

35 The insoluble fusion protein must first be solubilized in reagents which are compatible with the cleavage reagent desired. Such reagents include aqueous solutions

containing chaotropes (4 M urea, 4 M guanidine hydrochloride), detergent solutions (1% SDS, 1% Sarkosyl), or mixed organic acid/water solutions (50% acetic acid, 70% formic acid). Next, the solutions are treated with various chemical or enzymatic agents capable of cleaving the peptide bond at the desired amino acid (using reagents such as endoproteases Arg-C, Glu-C, Lys-C, Asp-N), or chemical reagents such as CNBr (cuts at Met), BNPS-skatole (cuts at Trp), or dilute acid (cuts at Asp-Pro)). For all of these agents, solutions are available which will dissolve the fusion protein and which will allow the reagents to act upon the fusion protein.

Alternatively, a suspension of the fusion protein also could be treated with the reagent. Even though the fusion protein is only sparingly soluble, some of the fusion protein is in solution and/or accessible to the reagent. Longer incubation of the reaction mixture will eventually result in complete cleavage of all of the fusion protein. Reaction time courses can be monitored either by SDS gel (observing the change in molecular weight of the fusion protein), or by reversed-phase HPLC.

**Separation of Peptide from Carrier Segment**

To remove the bulk of the carrier segment from the peptide, all that is required is to remove the solubilizing agent and to separate the insoluble carrier segment. Removal of the solubilizing agent can be done by dialysis, diafiltration, dilution, lyophilization, or other means readily available to the user. Removal of precipitated carrier segment may be made by filtration, centrifugation, or settling. The supernatant solution will contain substantially pure peptide, which in many cases can be used as is, or which can be further purified by methods standard to the art of peptide purification. If removal of trace remaining carrier segment is desired, passage of the supernatant over a hydrophobic resin such as phenyl-Sephacrose (Pharmacia Corp., Uppsala, Sweden) will

selectively remove the carrier segment, leaving the peptide in the flow-through fraction.

A substantial advantage of this approach is that the user does not need access to peptide synthesizers, and there also is a lower chance that the purified peptide contains deleterious side chain modifications. A recent test of biotechnology core facilities indicated that are extremely common; 50-60% of the peptides tested contained a modified peptide as the major component, even when the peptides were purified after synthesis (Smith, A.J. et al., 1992). The major cause of this was determined to be incomplete deprotection of amino acids after synthesis. The method of invention never adds these groups so this problem is avoided completely.

**USES OF CARRIER PROTEIN CONJUGATES AS PEPTIDE EQUIVALENTS**

**Production of Specific Protease Inhibitors**

As previously discussed, there are a number of applications wherein the carrier segment is best either left attached to the desired peptide or removed from it. There are a few applications in which either embodiment is allowable. One of these is the production of specific protease inhibitors. If a desired protein whose sequence is known is observed to be proteolytically cleaved at specific sites, the usual way to block cleavage is to add protease inhibitors. Since no single inhibitor can fully block the action of all proteases, screening of multiple inhibitors is required. In addition, such agents are often expensive to use at larger scale as well.

If the approximate location of the cleavage site is known, one then can create large quantities of fusion protein using methods described earlier which contains a peptide spanning the approximate site of protease cleavage. Addition of this fusion protein, or peptide prepared from the fusion protein, will protect the protein of interest from cleavage by mass action, i.e. the addition of a vast

excess of protease sites. The resultant fragment containing the carrier segment will then be easily removable by any of the methods noted previously.

#### 5 Use in Studies of Protein Modification Enzymes and Protein-Protein Interactions

Another use of the carrier protein conjugates is as

10 substrates for enzymes that covalently modify amino acid side chains of proteins, such as kinases, phosphatases, glycosidases, and the like. With the carrier segment removed, these peptides can be used in all of the standard assays typically used in the study of such enzymes. With the carrier segment attached, the peptides will be 15 substantially insoluble and capable of being immobilized to solid supports, which may have advantages in developing assays in microtiter plates. Similarly, peptides

20 increasingly are being used in studies of protein-protein interactions, in which case the selected peptide is usually a region of a protein which interacts with the selected region of a second protein. Again, either the free or carrier segment-attached peptide may be used for such studies. One additional potential advantage of the system described for these studies is that variants on the known peptide sequence may be readily prepared and tested, either 25 by preparing alternative cloned sequences through methods known to the art, or by using amber suppression expression systems which can substitute several different defined amino acids at a single site using a single vector as a

30 starting point (Interchange kit, Promega Corp, Madison, WI.).

Use in Protein Purification by Affinity Interactions

35 A large number of proteins interact with each other through specific protein-protein interaction domains. A carrier protein conjugate in which the ligand contains one of these domains could be immobilized and used in an affinity mode to selectively bind a protein of interest.

This method also can be used in the case where the peptide library has been identified by screening of a peptide display library using techniques well known to the art. The advantage in this usage is that large quantities of the desired peptide sequence can be easily and inexpensively produced, purified, and immobilized.

**Use in Cell Sorting**

Finally, some cells display receptors on their surfaces which are indicative of their status with respect to proliferation, differentiation, or other characteristic. If a peptidic ligand is known for these receptors, carrier protein conjugates might be used to separate the indicated cells from a mixed population. This could be by passage of cells over a surface coated with the carrier protein conjugate, settling of cells mixed with a fine suspension of the conjugate, or by mixing cells with a dilute solution of the conjugate followed by passage over a hydrophobic resin. Here, the ligand is adapted to selectively bind to a specific cell type or cells in a specific state of growth.

#### USERS OF CARRIER PROTEIN CONJUGATES AS IMMUNOLOGIC REAGENTS

##### 25 Production of Antibodies

The present invention also is useful in that it is adapted to be used as an immunogen for the generation of antibodies. The antibodies may be polyclonal or monoclonal. The monoclonal antibodies are produced by hybridoma cells, and polyclonal antibodies are produced in host animals according to methods known to the art. Because of the low antigenic nature of the carrier sequence, it is more likely that the antibodies will be raised against the ligands of interest rather than the carrier segment. In the case of monoclonal antibodies, this should allow a higher success rate and therefore less costly screening. In addition, the immunization with the carrier protein conjugate may be advantageous over

injection of native proteins in that the epitope of the resultant monoclonal antibody is predefined. Thus, an experiment would prepare several carrier protein conjugates containing different ligand segments of the desired protein, inject into host animals, and proceed to make monoclonal antibodies using the animal with the best initial polyclonal antibody titer. Moreover, using this technology the dose of immunogen influences antibody isotype which allows for enrichment of the desired antibody isotype.

The present invention is further directed to the production of antibodies raised against particles of the invention which are antigenic. The antibodies may be polyclonal (obtained for example by injecting antigens into a rabbit) or monoclonal, produced by hybridoma cells in accordance with the invention. The particulate antigens are polyvalent in nature. Therefore, it is more likely that in vitro immunization can be achieved more readily than with other forms of antigen. This may facilitate the production of human monoclonal antibodies.

Hybridoma cells then may be prepared by fusing lymphoid organ cells from an immunized animal with a tumor cell. Appropriately secreting hybridoma cells may thereafter be selected (Kohler & Milstein, 1976).

The present invention also is directed to the production of antibodies by taking the specific carrier segment, fusing any ligand and injecting the resultant carrier protein conjugate into a host animal which will produce antibodies to the ligand. The novelty of this invention is that an antibody to any ligand can be made if the ligand is fused to the specific carrier segment of the present invention.

The desired carrier protein conjugates are created by the combination of the carrier segment and the ligand. A fusion protein for antibody production does not need a cleavage segment between the carrier segment and the peptide. In antibody production, antigens typically are



As discussed above, submilligram amounts of immunogen are sufficient to elicit a useful immune response. This dosage level is comparable to that used for administration

35 lymphatic system.

immunogen to be transported to its destination in the because of the irritation in that region causing the actions of cells in the region. The immune cells interact released from the point of injection by leaching and by the 30 bloodstream to the regional lymph node. The antigens are point of injection and are transported through the injection. Gradually, however, antigens leach from the carrier protein conjugates remains at the spot of are injected into the animal body, the majority of the obviate the need for additional adjuvant. When immunogens 25 invention has sufficient intrinsic adjuvant activity to antigen at the site of injection. However, the present enhance the nonspecific immune response and entrap the Usually, immunogens are suspended in adjuvants to 20 activate the immune system.

the stomach do not destroy the immunogen before it can used in some circumstances when the digestive enzymes in Peroral administration, i.e., through the mouth, can be intraperitoneally (IP), i.e., into the peritoneal cavity. 15 intravenously (IV), i.e., into the vein; or the skin; intramuscularly, (IM), i.e., into the muscle; substance into the skin; subcutaneously (SC), i.e., beneath be carried out intradermally (ID), i.e., by injecting the administered parenterally. Parenteral administration can be 10 The immunogens prepared as described above can be

**Administering (Injecting) Carrier Protein Conjugates and Complexes as Antigens**

5 injected into the recipient animal.

Sub-milligram amounts of the fusion protein are then the carrier segment is required to elicit T-cell help. to separate the peptide from the carrier segment. In fact, injected into the host animal intact, so there is no need

of immunogens prepared by other methods, however as little

as 10 µg of carrier protein conjugate have been shown to elicit a robust humoral immune response in the absence of adjuvant. Although the lower dosage range may vary for different ligands, this represents a much lower amount of adjuvant free immunogen required than by many traditional methods known to the art.

Although the normal immunization schedules known to the art for different host animals are appropriate for the carrier protein conjugates of this invention, a single administration of 200 µg of immunogen also has been shown to be effective in eliciting a robust humoral immune response to the ligand. This can have significant advantages when dosage administration is technically difficult or time-consuming.

As previously discussed, the carrier segment acts as a carrier to elicit T-cell help for the ligand, and as an adjuvant for the attached ligand. The carrier segment also may exert these effects on a ligand which is admixed rather than covalently attached. In this case, a dilute suspension of carrier protein segment is vigorously mixed with the desired immunogen, and the complex is then injected into the host animal.

## 25 Vaccine

The immunogens prepared in accordance with the invention may be useful in the preparation of vaccines. In this case, the carrier protein conjugate may contain a portion of the amino acid sequence of an antigen of an infectious agent or a ligand from an environmental toxin for instance. The vaccine comprises a particulate immunogen described above and a physiologically acceptable excipient, such as sterile pyrogen-free physiological saline.

The ligand present in the carrier protein conjugate can be adapted to be administered to any vertebrate immune system, e.g., rabbit, mouse, goat, rat, hamster, dog, cat,

5 cattle, sheep, chicken, pigs and humans. It is within the scope of the present invention to combine virtually any ligand with the carrier segment. The optimal regimen for vaccination may differ from those discussed above for antibody production.

#### Uses of Carrier Protein Conjugate to Purify Antibodies

Two different methods can be used to purify antibodies using the fusion protein. Inclusion bodies comprised of the fusion protein can be mixed with crude antibody preparations to the target ligand. The solution can then be spun to pellet the added inclusion bodies and washed. This process removes all of the antibodies and serum components which do not bind to the fusion protein. The specific antibodies which bind to the inclusion bodies can then be eluted using conditions well-known in the art, and these antibodies can be separated from the inclusion bodies by again pelleting the inclusion bodies and removing the released antibodies. The small amount of fusion protein which is soluble then can be removed by brief contact with hydrophobic resins known to the art.

Conversely, the fusion protein can be linked to a solid support and the solid support can be incubated with the crude antibody to allow capture of the specific antibodies which bind to the fusion protein. These antibodies again can be released from the support using elution techniques well-known in the art. The purified antibodies then can be coupled to a solid support to provide an affinity purification matrix capable of purification of the protein which contains the antigenic sequence encoded by the peptide used for immunization. This can be done by incubating a crude solution containing the target protein to the antibody bound on the resin, removing unbound materials by washing the solid support and then eluting the proteins which have specifically bound to the resin.

In such an application, if the ligand containing

material is a protein, it is advantageous to retain the biological activity of the protein during the release of the protein from the resin. In such a case, some of the conditions which are used to release most antibodies from their ligands may be too harsh for the protein of interest to retain its bioactivity. Therefore, only that fraction of antibodies should be used for generation of the affinity resin that release under relatively mild conditions known as "soft release" conditions.

These can be isolated from the total antibody pool bound to the antigen by using the "soft release" conditions to dissociate the antibody from the fusion protein. This will ensure that the released antibody pool will contain primarily only those antibodies which dissociate from the antigen under mild conditions. Since such antibodies are normally isolated only after isolation of a monoclonal cell source which produces such an antibody, the current invention provides another advantage to the end user by simplifying the isolation of such antibodies from a polyclonal antibody pool.

#### Assay/Diagnostic Reagents

The present invention also is useful in the production of diagnostic reagents for use in diagnostic assays. The carrier protein conjugate, comprising the combination of solid supports such as test tubes, microtiter plate wells, dipsticks, membranes and the like. Solid supports utilized in the assays are well-known to the art. Examples of solid supports can be found in U.S. Patent 5,322,769 to *Bolling et al.* which is incorporated herein by reference for a description of the solid supports. Exemplary materials for such supports include hydrocarbon polymers such as polystyrene, polyethylene and polybutylene. Typically, the microtiter plates are coated with purified antigens or carrier protein conjugates. Alternatively,

microtiter plates that previously have been coated with monoclonal antibodies specific for the carrier protein conjugates could be used to capture them. The diagnostic reagents have a variety of uses. For example, a test sample suspected of having antibody to a particular analyte and a fluorescent enzyme or radiolabeled antibody is competitively reacted with the particular carrier protein conjugate on a solid support, and the amount of labeled antibody which binds to the particular antigen on the solid support is quantified. Particular carrier protein conjugates also are useful for agglutination reactions with antibodies. Other assays suitable for use with the carrier protein conjugates of the present invention are within the scope of those with knowledge in this particular art, some of which are described in the following paragraphs.

#### Types of Immunoassays

An ELISA process wherein the antibodies and/or carrier protein conjugates made by the process of the present invention used in combination with monoclonal antibodies, polyclonal antibodies, and soluble receptors also are contemplated. The advantage to this is that production and purification of carrier protein conjugates and subsequent antibodies are made much more quickly than under normal conditions.

#### KITS

The present invention also is directed to kits that utilize the process described. The kits are suitable for generating carrier protein conjugates and reliably making peptide/protein specific antibodies for use in a wide variety of techniques including protein purification, epitope mapping, detection by techniques such as Western Blotting, immunocytochemistry (ICC), immunoassays, and ELISA and for use in studies of protein/protein interactions.

A basic kit includes a container including the fusion protein carrier segment of the present invention which is a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence, and instructions for use.

5 Preferably, the nonantigenic fusion protein carrier segment is a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence having a length at least about 65 amino acids wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site).

15 Specifically, the fusion protein carrier segment is an amino acid sequence as illustrated in Fig. 1 [SEQ. ID. 1] or an amino acid sequence as illustrated in Fig. 3 [SEQ. ID. 2].

20 A second embodiment of the kit includes the vector encoding a carrier protein segment and instructions for its use. Such instructions may include those for the simple cloning, expression and purification of fusion proteins containing peptide antigens of choice in sufficient quantity for immunization of a host animal such as a chicken, mouse or rabbit, and for screening the resulting antibody pool. The customer clones in the DNA sequence corresponding to the peptide sequence of interest.

30 Ideally, the produced fusion protein could be injected into animals without an adjuvant or second carrier protein to produce an antigenic response comparable to or better than that produced by current technologies. The amounts of the various reagents in the kits can be varied depending on a number of factors, such as the optimum sensitivity of the process.

35 The instructions for use are suitable to enable an end user to carry out the desired test. By the term

"instructions for use," it is meant a tangible expression describing the reagent concentration for at least one assay method, parameters such as the relative amount of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions and the like. It is within the scope of this invention to provide manual test kits or test kits for use in automated analyzers.

A third embodiment for the kit may be a method for detection of an antibody directed against a particular antigen. Such a kit typically includes the following items in amounts sufficient for at least one assay:

1. Solid support: a solid support having bound thereto one or more carrier protein conjugates that will specifically react with a desired antibody. Preferably the solid support is a preformed microtiter plate having the appropriate carrier protein conjugates bound to it.
2. Buffer to remove unbound proteins.
3. Solutions for detection of bound analyte.
4. Instructions for use

A fourth embodiment for the kit is directed to a test kit for use in detecting the presence of proteins that bind a fusion protein in a test sample. The test kit consists of a container with a fusion protein, wherein the carrier segment comprises a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence and instructions. The antigen here, sometimes called an analyte, is the substance to be detected in a test sample. The antigen can be any substance for which there exists a naturally occurring, specific binding member such as an antibody. An analyte can be a substance that can bind to one or more specific members in an assay.

The following examples are presented to illustrate the advantages of the present invention and to assist one of ordinary skill in making and using the same. The examples

# EXAMPLES

are not intended in any way to otherwise limit the scope of the disclosure or protection granted by the patent.

### Example 1

#### Creation of a Carrier Protein Segment From a Naturally Occurring Protein

The starting protein in question was gene 10 protein of phage T7- normally a protein of molecular weight about 35 kD. Test fusions of the intact gene 10 protein with the p50 test antigen [SEQ. ID. 4] were prepared and injected into rabbits. The antibodies produced by the rabbits overwhelmingly reacted with the gene 10 portion of the fusion protein and not with the test antigen. Since this construct (according to the method of Lin et al., 1987) failed the criteria for low antigenicity described herein, the sequence of a fragment of the gene 10 protein was redesigned as discussed below to obtain the desired properties. The details of the vector cloning are presented in Example 2. This example describes the design process that resulted in the selection of the amino acid sequence used.

As described below, the intent was to create as short

a peptide sequence as possible which would be highly expressed and insoluble. A first attempt at creating a protein of 65 amino acids (carrier segment plus polylinker) was unsuccessful, but when 37 additional amino acids of designed sequence were added, expression was successful. The original sequence of the pGEMEX-1 amino acid sequence up to the site of the polylinker addition (Pvu2 site, Fig. 3 [SEQ. ID. 2]) is:

(H<sub>2</sub>N) - MASMGTGGQOM GTNQGKGVA AGDKLATFLK VEGGEVLTA  
ARTSVTTSRH MVRSSSGKS AQPVLGRTQ AAYLAPGEN - (COOH) [SEQ.  
ID. 6]

In designing the new sequence presented in Fig. 3, modifications were made as follows, which are in accordance with the design precepts in the Description of Invention section. Because the protein was already very hydrophobic,



gross changes in amino acid hydrophobicity were not required:

Site	Former Amino Acid	New Amino Acid(s)	Reason
4	M	V	eliminate met, conservative codon change
10	M	V	eliminate met, conservative codon change
16	K	H	eliminate lys, retain some charge at low pH
23	D	T	eliminate asp, half of unique Agel site (cloning)
24	K	G	eliminate lys, half of unique Agel site (cloning)
30	K	H	eliminate lys, retain some charge at low pH
35	E	T	eliminate glu
42	R	QH	eliminate arg, show that insertion into protein is tolerated
49	R	-	eliminate arg, show that deletion in protein is tolerated
51	M	V	eliminate met, conservative codon change
53	R	H	eliminate arg, retain some charge at low pH
58	G	A	remove gly from hydrophilic, possibly antigenic site
59	K	N	eliminate lys, conservative codon change
68	R	H	eliminate arg, retain some charge at low pH
78	E	N	eliminate glu, conservative codon change
79	N	Q	creation of Pvu2 site (cloning)

15

10

5

# Example 2

Production of Proteins by Certain Vector Constructs  
 Creation of pMK 136 (clone consisting of AAs 1-41 and 79-102 of Fig. 3)

Two oligonucleotides of the following sequence were synthesized by standard means:

5'GGC TAG CTA GCG TGA CTG GTG GAC AGC AAG TGG GTA ACC  
 MK9  
 AAG GTC ACG GTG TAG TTG CTG GAA CC 3' [SEQ. ID. 6]

5'GTC CGC TCG AGG TCG GAA TTC CCA GCT GAG CGA ACG CAG TCA  
 GGA CGG TAC CGC CAA ATA CAT GCA AGA ACA ACG CCA GAC CGG T  
 MK10  
 3' [SEQ. ID. 7]

The oligonucleotides were designed so that they could be dimerized with Taq DNA polymerase using a "primer dimer reaction", using a 3 bp overlap of the 3' ends of the two oligonucleotides. The site of the overlap was designed to contain a unique AgeI site, so that integrity of the overlap in the dimer could be verified. The dimerization reaction was accomplished in the presence of 50 pmoles each oligonucleotide, 1  $\mu$ l Amplitaq DNA polymerase, standard buffer, Mg, and nucleotide levels, and 35 thermal cycles consisting of 30 seconds at 70° C followed by 30 seconds of 95° C. The products of 15 standard 100  $\mu$ l reactions were pooled and the dimer purified by electrophoresis on a 10% native polyacrylamide gel. The dimer DNA was passively eluted overnight, extracted with phenol, and ethanol precipitated. The ends of the dimerized oligos were trimmed with restriction enzymes NheI and XhoI in standard buffers; the reaction was monitored by native PAGE gel. pGEMEX-1 vector (Promega Corp, product #P2211) was cut with restriction enzymes NheI and XhoI (monitored by agarose gel electrophoresis) and purified by phenol extraction and ethanol precipitation. The trimmed oligonucleotide dimers then were ligated into the cut

vector with T4 DNA ligase, then the ligation products were used to transform bacterial strain BL21(DE3) pLys (a standard T7 expression strain, Novagen Corp, Madison, WI, product #69451-2), using the protocol recommended by the manufacturer. The cells were plated onto LB-amp plates and grown overnight at 37° C. Colonies were picked into LB amp liquid culture, and plasmid was purified and analyzed for proper inserts by standard techniques. The DNA sequence across the area of interest for a plasmid from one positive clone, pMK136, was determined to be correct by standard techniques.

Expression of protein in the resultant strain was tested using conditions as described in the review article by Studier et al 1990. Reference also is made to U.S. Patent 4,952,496 to Studier et al, which covers the use of T7 RNA polymerase in expression systems. The resultant clone was grown in LB - amp medium induced with 0.5 mM IPTG, and protein products analyzed by SDS-PAGE. No significant protein expression could be detected. Thus, this first attempt at production of a vector encoding a carrier segment failed, possibly due to the short length of the encoded protein. The encoded protein in this case is 65 amino acids long; 41 amino acids before the Pvu2 site, and 24 amino acids encoded by the polylinker. The plasmid created in this section, pMK 136, was used as the starting point for the creation of the successful vector, pMK 149, and hence is included in this description.

### 30 Creation of pMK 144 (clone as depicted in Fig. 3)

Before cloning into pMK 136, a first step was to get rid of the pLys plasmid. This was accomplished by digesting a preparation of plasmid from pMK 136 with EcoRV, transforming into bacterial strain JM109 (Promega Corp., Madison, WI., product #L2001), plating on LB-amp, and testing colonies for lack of resistance to chloramphenicol and resistance to ampicillin. A plasmid preparation was

made from one such colony, and digested with Pvu2 under standard conditions (reaction monitored by agarose gel electrophoresis).

Two oligonucleotides of the following sequence were synthesized by standard means:

5'CT GGT TGC CCG GAG CCA GAT ACG CTG CCT GAG TAT GAC CCA  
GAA CAG GGA ACT GAG CGG AGT TAG CGC TGG AGA TGG AAT GTA CCA  
CGT GAG AAG TGG TCA CGG ACG TAT G 3' [SEQ. ID. 8]

5'CA TAC CTC CGT GAC CAC TTC TCA CGT GGT ACA TTC CAT CTC  
CAG CGC TAA CTC CGC TCA GTT CCC TGT TCT GGG TCA TAC TCA GGC  
AGC GTA TCT GGC TCC GGG CAA CCA G 3' [SEQ. ID. 9]

The two oligonucleotides were hybridized to each other by heating to 95° C for 5 minutes followed by slow cooling to room temperature, then ligated into the cut vector with T4 DNA ligase, then the ligation products were used to transform bacterial strain BL21(DE3) pLysS (a standard T7 expression strain, Novagen Corp, Madison, WI, product #69451-2), using the protocol recommended by the manufacturer. The cells were plated onto LB-amp plates and grown overnight at 37° C. Colonies were picked into LB amp liquid culture, and plasmid was purified and analyzed for proper inserts by standard techniques. The DNA sequence across the area of interest for a plasmid from one positive clone, pMK144, was determined to be correct by standard techniques. A similar strain, pMK 149, was created in JM109 which lacked the pLysS plasmid, by the aforementioned EcoRV digest technique. Plasmid from these cells was sequenced and used for all subsequent vector clonings. Expression of protein in the pMK144 strain was tested using conditions as described in the review article by Studier et al (1990, supra.). The resultant clone was grown in LB - amp medium induced with 0.5 mM IPTG, and protein products analyzed by SDS-PAGE. As discussed in

Example 2, expression from this strain was good, and serves as the carrier protein segment described in Fig. 3 and the preferred embodiment of the patent for a carrier segment/polylinker segment expression vector.

Creation of pMK 160 (insertion of p50 N-terminal epitopic peptide coding sequence into polylinker of pMK144)

A plasmid preparation was made from one such colony, and digested with Hind3 and NotI under standard conditions (reaction monitored by agarose gel electrophoresis).

Two oligonucleotides of the following sequence were synthesized by standard means; these encoded the synthesis of a 15-mer peptide sequence which is the N-terminal sequence of the eukaryotic transcription factor p50, with an additional lysine at the junction between the peptide and the carrier segment (usable to test cleavage with LysC), and an amber stop codon at the end of the peptide segment.

5'GG CCA AAA TGG CAG AAG ATG ATC CAT ATT TGG GAA GGC CTG  
AAC AAA TGT AG3' [SEQ. ID. 10]  
MK19

5'AG CTC TAC ATT TGT TCA GGC CTT CCC AAA TAT GGA TCA TCT  
TCT GCC ATT TT 3' [SEQ. ID. 11]

The two oligonucleotides were hybridized to each other by heating to 95° C for 5 minutes followed by slow cooling to room temperature, then ligated into the cut vector with T4 DNA ligase. The ligation products then were cut with SphI under standard conditions to linearize any residual intact vector, then the ligation products were used to transform bacterial strain BL21(DE3) pLysS (a standard T7 expression strain, Novagen Corp, Madison, WI, product #69451-2), using the protocol recommended by the manufacturer. The cells were plated onto LB-amp plates and grown overnight at 37° C. Colonies were picked into LB amp liquid culture, and plasmid was purified and analyzed for proper inserts by standard techniques. The DNA sequence

across the area of interest for a plasmid from one positive clone, pMK160, was determined to be correct by standard techniques.

Expression of protein in the pMK160 strain was tested using conditions as above.

#### Creation of pMK190-210:

These constructs, which were used in the expression and properties example below, were created by a cloning and expression strategy very similar to that used for pMK160. Specifically, two complementary oligonucleotides were created which coded for the peptide of interest and with ends compatible with in-frame cloning into the NotI-Hind3 site. The only extra feature of the oligos was that they were designed with 3 extra nucleotides at one end in order to create a new NheI site at the Hind3 junction. This made screening for inserts easier, since digestion of an insert-containing plasmid with NheI liberated a fragment of about 300 bp, whose size could accurately be determined by acrylamide gel electrophoresis. Otherwise, cloning and expression were as per standard protocol described above.

#### General Note About Comparing Vector-Encoded Proteins to Carrier Segment/Polylinker Definition in Fig. 3.

The pMK144 expression strain and the pMK149 expression vector from which all fusion proteins used in the examples were derived, do not correspond exactly in encoded amino acid sequence to the carrier/polylinker segment of the fusion proteins. In the original vector, the first translation termination codon is encountered after amino acid leu102. In creating the fusion proteins used in the examples, for instance pMK160, the oligonucleotides encoding the peptide of interest were cloned into a NotI/Hind3 site, and contained a stop codon after the last amino acid of the desired peptide. This cloning strategy results in amino acids 95-102 of the sequence in Fig. 3 not being expressed in the fusion protein. Since

amino acid 96 of Fig. 3 is a cysteine residue, if one wishes to couple a ligand to the carrier segment with a sulphydrylreactive reagent, one can use the vector as is. Otherwise, it is advisable to insert a stop codon anywhere in the polylinker to avoid problems with the formation of disulfide bonds.

#### Expression and Purification of Carrier Segment-Containing Fusion Proteins:

50 ml LB amp shake flasks were seeded with 1-5  $\mu$ l of glycerol stock of each expression strain and grown at 37°C overnight. In the morning, 30 ml of overnight culture was centrifuged for 5-10 minutes at 1,000-4,000 x g at room temperature. The pellet from each culture was then transferred into 1 L cultures containing LB-amp prewarmed to 37°C, and incubated with shaking until an optical density at 600 nm of 0.5-1.0 was reached (about 3-4 hours after seeding). At that time, IPTG was added to 0.5 mM to induce expression, and cells were allowed to shake for 3-4 hours after induction. Samples could be taken for SDS-PAGE analysis as desired. After this time, cells were harvested by centrifugation at 3,000-5,000 x g for >10 minutes. Cells then were processed directly, or stored for up to two weeks at -70°C prior to use.

Cells were resuspended in 40 ml of buffer A (10 mM TrisHCl pH 8.0, 130 mM NaCl, 1 mM DTT), transferred to a 100 ml plastic beaker, chilled on ice water for 5 minutes, then sonicated (still in ice water batch) for 3 minutes with a Sonics and Materials VCX600 sonicator equipped with their standard macrotip, 0.5 seconds on, 0.5 seconds off, at a power setting of 55% (about 330 watts). Foaming was avoided to maximize cell breakage. After sonication, 4.5 ml of 20% sodium deoxycholate was added, and samples were again sonicated for 30 seconds. The lysates then were transferred to centrifuge tubes and spun at 15,000-20,000 x g for 10 minutes at 4-10°C (JA18 rotor). The supernatants were discarded, an optional second wash with



2% sodium Deoxycholate in buffer A was performed as desired, then the pellets were resuspended by brief sonication in isotonic phosphate buffered saline pH 7.4 containing 1 mM DTT and 1% Triton X-100. (Note: the Triton X-100 step may be omitted if desired to obtain material of slightly lesser purity and containing trace deoxycholate). The samples were pelleted as before, then washed at least 1x with isotonic phosphate buffered saline lacking excipients, then resuspended in 10 ml of the same buffer. Purified fusion proteins or carrier segment was then stored at -20° for as long as 6 months before use, if desired, and were ready for injection. In some cases, samples stored for long periods needed to be sonicated to reproduce a fine suspension before injection.

#### Expression Results:

The protein was assayed as described in Example 3. which follows this paragraph. Table 1 presents examples of fusion proteins produced using the described invention and some properties thereof, including the amino acid sequence of the fused peptide, the size and charge of the fused peptide, the solubility in aqueous solution and retention time by reversed-phase HPLC, the optical density at which cells were induced and harvested, and the yield of purified fusion protein, in mg/liter. Table 1 indicates the strain number, the parent protein from which the peptide was selected, the number of amino acids in the attached peptide, the net charge of the attached peptide in neutral aqueous solutions, the optical density at which the cells were induced (harvested, if there is a second number), and the number of milligrams of fusion protein isolated from a liter of LB amp culture medium.

Bacterial Strain	Antigen Name	# of AA in Peptide	Net Charge	Sequence of the Insert (1 letter amino acid code)	SEQ. ID No.	Solubility (ug/ml)	HPLC Retention Time	O.D.	Yield (mg/L)
MK144	base	0	0	none (for reference purposes)	n.a.	0.81	33.1	0.7/1.23	11
MK160	p50	15	-2	KMAEDDPYLGRPEQM	4	4.7	30.3	0.65/1.36	26
MK189	P1MT substrate	13	1	MKQVNSAYEVIL	12	1	31.2	1.1	14
MK190	AP2	19	3	MSHTDNNAKSSDKEEKKHRK	13	2.3	29.6	1.2	6
MK201	SP1	19	3	CKDSEGRGSDPGKKKQHI	14	---	---	0.558/1.15	19
MK202	Rantes	17	0	NPEKKWVREYINSLIMS	15	---	---	0.52/0.95	37
MK203	MCAF	21	2	KQKVVQDSMDHLDKQTQPKT	16	---	---	.809/1.3	31
MK204	IL2RG	7	0	YTLKPET	17	---	---	.727/1.32	33
MK205	TGFβ1	25	0	YYSLDTQYSKVLALNQINPGASAA	18	---	---	.59/.9	30
MK206	EIF-2α	10	2	ILSELRRRR	19	---	---	.878/2.22	71
MK208	P1MT	13	1	LMGVITYPLTDKEKQWSWK	20	---	---	.35/.58	17
MK209	p49	19	3	ETSSLKIQTLAGHGGRRL	21	---	---	.843/1.7	36
MK210	SP1tail	12	-1	MNSSSVPGDPPM	22	---	---	.505/1.25	36

TABLE 1

There was little or no measurable expression of protein encoded by the plasmid in pMK136, as detected by SDS-PAGE or HPLC. Expression from the longer carrier segment vector pMK144 was substantial (11 mg/L), and expression of all the fusion proteins derived from it were above 5 mg/L culture (range 6-71 mg/Liter, mean 27 mg/Liter, standard deviation 16 mg/Liter).

### Example 3

#### Analysis of Purity and Properties of Carrier Segment and Fusion Proteins

**Protein Assay:** Samples of the fusion protein suspension were dissolved in an equal volume of glacial acetic acid, then diluted further 1:5 with 50% acetic acid. Diluted soluble samples then were assayed using Pierce Corp. Coomassie Plus Assay Reagent, using bovine serum albumin diluted in 50% acetic acid as a protein concentration standard. 10 µl of sample was added to 200 µl reagent, then absorbances were read at 595 nm.

**SDS-PAGE Analysis of purity:** Samples of the fusion protein suspension were dissolved in 9 volumes of 4x Laemmli SDS gel loading buffer, heated to 95° C for 5 minutes, then 20-40 µg of protein as estimated by the assay above were loaded onto Novex 4-20% SDS-PAGE gels (10 well combs). The running buffer contained 0.2-0.3% SDS instead of the usual 0.1%, in order to maintain the fusion protein in solution. After electrophoresis by manufacturer's standard conditions, the gels were stained with Coomassie Blue as per standard methods. The gel indicated a single major band with contaminant bands at less than 10% of total protein.

**HPLC Analysis of purity and retention time:** A sample was prepared as for the protein assay in acetic acid and analyzed by reversed phase high pressure liquid chromatography (HPLC). The stationary phase was a Vydac C-18 TP column, 10 µm silica, 4.6x250 mm dimensions. The mobile phase was standard (0.1% trifluoroacetic acid in

water/acetonitrile), flow rate was 1 ml/minute, and detection was by UV absorbance at 214 nm, 0.3 AUFS. A 20  $\mu$ l sample was injected, and eluted with a 40 minute linear gradient from 20%-60% acetonitrile. The results are depicted graphically in Figs. 5A and 5B (HPLC) and numerically in Table 1 (*supra*). Retention times varied from 29.6 to 33.1 minutes (50-54% acetonitrile); quite late elution for proteins of this size thereby indicating their high hydrophobicity. Other than the large peak at the injection due to the acetic acid and small background peaks, which could be shown to be due to impurities in the acetic acid, the expressed protein eluted as a single sharp peak, in agreement with the SDS-PAGE results.

#### HPLC Analysis of Solubility: Samples of several

15 fusions were allowed to stand in isotonic phosphate-buffered saline at 4° for several days with mixing until saturation was reached as estimated by the Protein Assay above. A protein standard was prepared by diluting an acetic acid-solubilized sample of protein from PMK160 until it was estimated to be about 100  $\mu$ g/ml. This was aliquoted after confirmation of protein concentration by the protein assay above (final concentration 95  $\mu$ g/ml). A serial 2-fold dilution series from 6 down to 0.75  $\mu$ g/ml was assayed by HPLC as above, peak heights were measured, and a standard curve was plotted. Samples of saturated fusion proteins were diluted with an equal volume of glacial acetic acid, and assayed by HPLC relative to the PMK160 sample. Although the peak elution positions varied slightly from fusion to fusion, the peak shapes were very consistent, as can be seen in Figs. 5A and 5B. The results, presented in Table 1, indicate that solubilities of the base protein (with extension as noted above) and fusions ranged from 0.8-4.7  $\mu$ g/ml. The sizes of the peptide fusions tested ranged from 14-19 amino acids, and the net charge at neutral pH ranged from -3 to 3.

FAB-MS analysis of protein size: A purified sample of fusion protein purified from PMK160 was submitted to the

30 the p50 carrier protein conjugate.  
 correlates with the amount of specific antibody bound to  
 The optical density of the colorimetric reaction directly  
 developing the reaction with the appropriate substrate.  
 detected using an anti-chicken antibody conjugate and  
 temperature. The amount of specific antibody bound was  
 concentrations of the sample for 1.5 hours at room  
 25 specific antibody titers by incubating various  
 wells then were used to analyze immunoglobulin samples for  
 nonspecific binding of proteins. The coated and blocked  
 a solution of 1% w/v bovine serum albumin to block  
 PBS containing 0.2% Tween 20 and then incubated 1 hour with  
 20 4°C. The wells of the plates were washed four times with  
 was coated onto 96 well plates and incubated 14-18 hours at  
 sequence and suspended in phosphate buffered saline (PBS)  
 carrier protein conjugate derived from the p50 protein  
 to be immobilized onto solid surfaces. Briefly, soluble  
 15 capitalizing on the capacity of carrier protein conjugates  
 diagrammatically illustrated in Fig. 6) was performed by  
 An indirect ELISA (enzyme linked immunosorbent assay

10 Immobilization of Carrier Protein Conjugates on  
Solid Surfaces  
**Example 4**

5 Kratos Corporation (Ramsey, NJ) for a demonstration run of  
 their Kompact fast-atom bombardment mass spectrometer. As  
 assayed by their standard methods and presented in Fig. 5B,  
 the detected molecular weight of the major species (M+1)  
 was 11,088 versus 11,086 as deduced from the sequence of  
 the vector. The difference is within the error of the  
 instrument.

**Example 5**

Infection of Proteins into Animals and Development of  
Antigenic Response by Animals Predominantly Directed  
Against the Ligand of Interest

5

Female BALB/c mice (three per group) were immunized IP with 100µg per injection of p50 carrier protein conjugate suspended in an equal volume (100µl) of Complete Freund's Adjuvant. The mice were boosted twice at four week intervals with the same amount of immunogen in incomplete Freund's Adjuvant. Two weeks after the last injection the mice were euthanized and the serum was collected. The indirect ELISA. Results from wells coated with the carrier protein (base) were compared to results from adjacent wells coated with the p50 carrier protein conjugate (160/p50). These results, shown in Fig. 7 as the mean OD per group per dilution, demonstrate that the vast majority of the specific antibody was preferentially directed against the peptide of interest.

20

**Example 6**

Ability of System to Allow Antibodies to be Produced  
Without the Use of Adjuvant

25

The antigenic response of mice to a fusion protein made between the carrier protein and a peptide segment derived from p50 was assessed with and without a variety of adjuvants. The experiment was conducted using the same injection regimen as was described in the preceding example. Six different adjuvants were used for comparison to injection with an equal amount (100µg) of p50 carrier protein conjugate alone (1x Genie) and 200µg of p50 carrier protein conjugate alone (2x Genie). The six different adjuvant groups consisted of Complete Freund's Adjuvant with the primary immunization followed by incomplete Freund's Adjuvant at the boosts (CF/IF), Complete Freund's Adjuvant at the primary immunization and no adjuvant with the boosts (CF/none), a solution of 0.2 mg alum and 1µg

35

30

saponin per injection (ISCOM), 0.4 mg alum per injection (Alum), 2.5 mg dextran sulfate per injection (Dextran Sul) or 0.7 mg poly [I,C] per injection (Poly IC). Immunization with Freund's Adjuvant and no immunogen was used as the negative control (Control). In all cases, an equal volume of adjuvant (100 $\mu$ l) was used with the immunogen. Injections without adjuvant (1X Genie and 2X Genie) also were normalized for volume using pyrogen-free saline solution. The serum titers of three mice per treatment group were assessed by indirect ELISA two weeks after the last boost. The results in Fig. 8 show that the specific antibody response of mice immunized with carrier peptide conjugate alone is comparable to that of mice injected with the immunogen suspended in adjuvant.

#### Example 7

##### Stimulation of Antigenic Response Over a Broad Antigen Dose Range

Example 7 is directed to the antigenic response of mice to various doses of a fusion protein made between the carrier protein and a peptide segment derived from p50. Mice were injected with 100 $\mu$ g antigen IP three times at four week intervals as previously described. Two weeks following the last injection, mice were euthanized and serum collected. Serum titers of antibody against the p50 carrier protein conjugate were assessed by indirect ELISA.

The results are expressed as the mean OD<sub>410</sub> of sera from three BALB/c mice per treatment group. Fig. 9A illustrates the antibody titers from mice immunized with 100  $\mu$ g (1 mg/ml - 0.1 mg/ml respectively), p50 carrier protein conjugate suspended in Freund's adjuvant (complete at the primary and incomplete with each boost). Fig. 9B illustrates the antibody titers from mice immunized with 200  $\mu$ g - 10 $\mu$ g (2 mg/ml - 0.1 mg/ml respectively), fusion peptide in the absence of adjuvant. These results demonstrate that the carrier protein conjugate is capable

of stimulating a robust immune response of a wide range of doses with and without adjuvant. Mice immunized with adjuvant only (adj. only) were used as the negative control.

5

### Example 8

Ability of System to Induce Significant Antibody Response with a Single Injection

10 Female BALB/c mice were immunized IP with a single 200 $\mu$ g (2mg 1x) injection of a fusion protein made between the carrier protein and a peptide segment derived from p50. For comparison, age and gender-matched BALB/c mice were immunized with three IP injections of 100  $\mu$ g p50 protein 15 carrier conjugate in Freund's adjuvant (1 mg +) or 200 $\mu$ g (2 mg) or 100 $\mu$ g (1 mg) immunogen without adjuvant, all as previously described. Mice injected with adjuvant only (adj. only) were used as the negative control. Ten weeks 20 following the primary immunization, mice were euthanized and serum collected. Serum antibody titers against the p50 carrier protein conjugate were assessed by indirect ELISA. The results are expressed as the mean OD<sub>450</sub> of serum from three mice per treatment group. As illustrated in Fig. 10, 25 mice that received a single injection at the initiation of the study had a significant specific antibody response ten weeks later. The titers were comparable to those of other mice that had received multiple boosts with or without adjuvant.

30

### Example 9

Production of Polyclonal Antibodies Using the System of the Present Invention with Immunization of Various Vertebrate Species and Routes of Immunization

35

To demonstrate the versatility of the system, mice, rabbits and chickens were immunized with the p50 carrier protein conjugate of the present invention in Freund's adjuvant.

40

Female BALB/c mice and female New Zealand white rabbits were immunized with three injections, separated by



three week intervals, via IP and SC routes, respectively. Two weeks following the last injection, the animals were euthanized and serum collected. White Leghorn laying hens were immunized by four weekly IM injections. Eggs were collected one week after the last injection for the isolation of antibody from the yolk.

The specific antibody titers of the animals to the p50 carrier protein conjugate and to the carrier (base) segment were determined by indirect ELISA as described in Example 4. Fig. 11A illustrates the mean titers of separate determinations showing high specific antibody titers to the peptide of interest in the serum of mice immunized by an IP route of injection. The specific antibody response of rabbits immunized via SC injections with the same p50 carrier protein conjugate is shown in Fig. 11B. Similarly, a high titer was achieved against the ligand of interest. Likewise, the specific antibody response of chickens immunized IM with p50 carrier protein conjugate is predominantly directed against the ligand portion of the molecule (Fig. 11C). Taken together, these data demonstrate the utility of this system in various vertebrate animal species using different routes of injection.

#### Example 10

##### Production of Polyclonal Antibodies Using This System Which Recognizes Both the Ligand and the Full Length Protein For Immunogen and the Full Length Protein From Which the Ligand Was Derived

Another important use of the present invention is to generate antibodies that will bind to the full length protein from which the peptide ligand was derived. To verify this use, antibodies were generated in mice using the p50 carrier protein conjugate with and without various exogenous adjuvants as described in Example 6. Specific antibody from the sera of these mice was evaluated by indirect ELISA, as previously described, comparing binding of antibody to p50 carrier protein conjugate to that of the

full length p50 protein coated onto adjacent wells. As illustrated in Fig. 12, binding of specific antibody to the p50 carrier protein conjugate (peptide) was comparable to that of the p50 protein (Protein). Indeed the slight enhancement in binding to the full length protein was likely due to a small portion of the specific antibodies binding to the carrier portion of the carrier protein conjugate. The results are expressed as the mean  $\pm$  SD OD<sub>410</sub> of three mice per treatment group.

10

#### Example 11

##### Production of High Proportions of Peptide-Specific Polyclonal Antibodies and Peptide-Specific Soft-Release Polyclonal Antibodies

15

White Leghorn hens (chickens) were immunized with four weekly IM injections of a carrier protein conjugate derived from the gamma common chain protein with Freund's adjuvant as previously described. Eggs were collected several weeks after the last immunization and IgY antibody was purified from the yolks by sequential precipitation (IgY fx). Specific antibody was purified by affinity chromatography of the IgY fraction using the immunogen linked to an agarose resin. Soft release antibody was eluted with 2 M MgCl<sub>2</sub>, pH 6.9 (soft release), whereas total specific antibody was eluted using 3 M MgCl<sub>2</sub>, pH 3.0 (hard release). Specific antibody titers were assessed by indirect ELISA. Reference is made to Fig. 13 for the results. The results demonstrate 7.6% total specific antibody (soft- and hard-release) and 1.5% specific soft-release antibody.

30

#### Example 12

##### Mitogenic Capacity of Fusion Peptide for Murine Splenocyte

35

Spleens of unimmunized female BALB/c mice were removed and monodispersed using frosted glass slides. Cells were resuspended at  $10^6$  c/ml in RPMI 1640 containing 10% fetal bovine serum (FBS). Cell suspensions were incubated in 96 well flat-bottom plates (100  $\mu$ l/well) and incubated for 72

40

hours at 37°C, 5% CO<sub>2</sub> in medium alone (none) or medium containing 5 µg/ml Con A, 10 µg/ml PHA, 5 µg/ml LPS or 5 µg/ml p50 carrier protein conjugate. Cellular proliferation was assessed following 72 hour incubation by LDH quantitation following cell lysis with a detergent solution.

Reference is made to Fig. 14 for the results of this experiment, which demonstrates that the proliferative response to the carrier protein conjugate (CPG) is comparable to that in response to ConA, PHA and LPS in spleen cells from unimmunized mice. This suggests the inherent mitogenic activity of the carrier protein conjugate. The results are expressed as the mean  $\pm$  SD of three mice per treatment group. Assays were performed in triplicate.

### Example 13

#### Isotype Varies with Immunogen Concentration in the Absence of Adjuvant

To determine the influence of antigen dose on resulting antibody isotype, BALB/c mice were immunized 3 times IP with 0.2ml p50 fusion protein in pyrogen-free phosphate buffered saline (no adjuvant) at 3 week intervals. Two weeks following the last injection, the mice were bled and euthanized. The predominant serum antibody isotypes were determined using the SangStat® isotyping kit and confirmed by indirect ELISA. Reference is made to Table 2 for the results, which are expressed as the rank order of predominant isotypes of 3 to 6 mice per treatment group.

Table 2

Immunogen Concentration Effects on Isotype Selection

Concentration (mg/ml)	Isotype
2	IgG1
1	IgG2b/1
0.5	IgG2a/1
0.2	IgG3/2a
0.1	IgG2a/2b

10 The results indicate that immunization with high amounts of antigen yields predominantly IgG<sub>1</sub> antibody whereas low amounts typically yield predominantly IgG<sub>2a</sub> and IgG<sub>2b</sub> antibodies.

15 It is understood that the invention is not confined to the particular construction and arrangements herein illustrated and described, but embraces such modified forms thereof and come within the scope of the claims following the bibliography.

## BIBLIOGRAPHY

- U.S. Patent 5,322,769 to Bolling et al.  
 U.S. Patent 4,743,679 to Cohen et al.  
 U.S. Patent 4,512,922 to Jones et al.  
 U.S. Patent 5,302,526 to Keck et al.  
 U.S. Patent 5,008,373 to Kingsman et al.  
 U.S. Patent 4,952,496 to Studier et al.  
 U.S. Patent 5,322,930 to Tarnowski et al.  
 Bolivar et al, 1977, *Gene* 2:95.
1159. Clewell, D. R. et al, 1969, *Proc Nat Acad Sci USA* 62: 2110.
- Cohen, S.N. , 1972, *Proc Nat Acad Sci USA* 69: 2110.
- 16). *Current Protocols in Molecular Biology* (1994; chapter Klein, J., 1990 *Immunology*, Blackwell Scientific Publications, Inc. Massachusetts, 269-293.
- Kohler & Milstein, 1976, *Nature*, 296: 495.
- Lin, S. et al., 1987, *Biochemistry*, 26: 5267-5274.
- Maniatis et al., 1989, *Molecular Cloning; A Laboratory Manual*, 2d. Ed.:254
- Santo, C. et al., 1992, *Science* 258: 120-122.
- Smith, A. J. et al., 1992, *Techniques in Protein Chemistry III*, 219-229.
- Studier F. W., et al, 1990, *Meth. Enzym.* 185: 60-89.
- Tae H. J., et al., 1983, *Methods in Enzymology* (Chapter 51), Academic Press, Inc., 91: 580-609.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: Knuth, Mark W  
 Haak-Frendscho, Mary  
 Shultz, John W  
 Lesley, Scott A  
 Villars, Catherine E

(ii) TITLE OF INVENTION: HIGH LEVEL EXPRESSION AND FACILE  
 PURIFICATION OF PROTEINS, PEPTIDES AND CONJUGATES FOR  
 IMMUNIZATION, PURIFICATION AND DETECTION APPLICATIONS

(iii) NUMBER OF SEQUENCES: 22

(iv) CORRESPONDENCE ADDRESS:  
 (A) ADDRESSEE: Dewitt Ross & Stevens, S.C.  
 (B) STREET: 8000 Excelsior Drive  
 (C) CITY: Madison  
 (D) STATE: WI  
 (E) COUNTRY: USA  
 (F) ZIP: 53717-1914

(v) COMPUTER READABLE FORM:  
 (A) MEDIUM TYPE: floppy disk  
 (B) COMPUTER: IBM PC compatible  
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS  
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:  
 (A) APPLICATION NUMBER: US  
 (B) FILING DATE:  
 (C) CLASSIFICATION:

(vii) ATTORNEY/AGENT INFORMATION:  
 (A) NAME: Sara, Charles S  
 (B) REGISTRATION NUMBER: 30,492  
 (C) REFERENCE/DOCKET NUMBER: 34506.039

(ix) TELECOMMUNICATION INFORMATION:  
 (A) TELEPHONE: 608-831-2100  
 (B) TELEFAX: 608-831-2106

## (2) INFORMATION FOR SEQ ID NO:1:

## (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 79 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met Ala Ser Val Thr Gly Gln Gln Val Gly Thr Asn Gln Gly His  
1 5 10 15  
Gly Val Val Ala Ala Gly Thr Gly Leu Ala Leu Phe Leu His Val Phe  
20 25 30  
Gly Gly Thr Val Leu Thr Ala Phe Ala Gln His Thr Ser Val Thr Thr  
35 40 45  
Ser His Val Val His Ser Ile Ser Ser Ala Asn Ser Ala Gln Phe Pro  
50 55 60  
Val Leu Gly His Thr Gln Ala Ala Tyr Leu Ala Pro Gly Asn Gln  
70 75

## (2) INFORMATION FOR SEQ ID NO:2:

## (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 102 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Ser Val Thr Gly Gln Gln Val Gly Thr Asn Gln Gly His  
1 5 10 15  
Gly Val Val Ala Ala Gly Thr Gly Leu Ala Leu Phe Leu His Val Phe  
20 25 30  
Gly Gly Thr Val Leu Thr Ala Phe Ala Gln His Thr Ser Val Thr Thr  
35 40 45  
Ser His Val Val His Ser Ile Ser Ser Ala Asn Ser Ala Gln Phe Pro  
50 55 60  
Val Leu Gly His Thr Gln Ala Ala Tyr Leu Ala Pro Gly Asn Gln Leu  
70 75 80

77

Gly Ile Pro Thr Ser Arg Asp Pro Gly Pro Leu Asp Ala Ala Cys  
85 90 95  
Ile Ser Leu Ser Ile Leu  
100

(2) INFORMATION FOR SEQ ID NO:3:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: unknown  
(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ileu Gly Ile Pro Thr Ser Arg Asp Pro Gly Pro Leu Asp Ala Ala  
1 5 10 15  
Cys Ile Ser Leu Ser Ile Leu  
20

(2) INFORMATION FOR SEQ ID NO:4:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: unknown  
(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Lys Met Ala Glu Asp Asp Pro Tyr Leu Gly Arg Pro Glu Gln Met  
1 5 10 15



(2) INFORMATION FOR SEQ ID NO:5:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 79 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Ala Ser Met Thr Gly Gly Gln Met Gly Thr Asn Gln Gly Lys  
1 5 10 15

Gly Val Val Ala Ala Gly Asp Lys Leu Ala Leu Phe Leu Lys Val Phe  
20 25 30

Gly Gly Gln Val Leu Thr Ala Phe Ala Arg Thr Ser Val Thr Thr Ser  
35 40 45

Arg His Met Val Arg Ser Ile Ser Ser Gly Lys Ser Ala Gln Phe Pro  
50 55 60

Val Leu Gly Arg Thr Gln Ala Ala Tyr Leu Ala Pro Gly Gln Asn  
65 70 75

(2) INFORMATION FOR SEQ ID NO:6:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: DNA (genomic)

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GGCTAGCTAG CGTGAAGTGGT GGACAGCAAG TGGGACTAA CCAAGGTAC GGTGAGTTG 60

CTGCTGAAC C

(2) INFORMATION FOR SEQ ID NO:7:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 85 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: DNA (genomic)

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GTCCGCTCGA GGTCCGAATT CCCAGCTGAG CGAACGCCAGT CAGGACGGTA CCGCCAATA 60  
CATGCAAGAA CAAGGCCAGA CCGGT 85

(2) INFORMATION FOR SEQ ID NO:8:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 111 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: DNA (genomic)

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTGGTGGCC GAGGCCAGAT ACCCTGCTG AGTATGACCC AGAACAGGGA ACTGAGCCGA 60  
GTAGCGCTG GAGATGAAT GTACCACGTG AGAAGTGGTC ACGGAGGTAT G 111

(2) INFORMATION FOR SEQ ID NO:9:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 111 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: DNA (genomic)

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CATACCTCCG TGACCACTTC TCACGTGGTA CATTCCATCT CCAGCGCTAA CTCGCTCAG 60  
TTCCTGTTC TGGTCAATAC TCAGGCAAGC TATCTGGCTC CGGCAACCA G 111

(2) INFORMATION FOR SEQ ID NO:10:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 52 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: DNA (genomic)

(X1) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GGCCAAATG GCAGAAGATG ATCCATATT GGAAGGCTT GAACAAATGT AG

52

(2) INFORMATION FOR SEQ ID NO:11:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 52 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: DNA (genomic)

(X1) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AGCTTACAT TTGTTCAAGC CTTCACCAAT ATGATCATC TTCTGCCATT TT

52

(2) INFORMATION FOR SEQ ID NO:12:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(X1) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Lys Gln Val Val Asn Ser Ala Tyr Gln Val Ile Leu

10

5

1

## (2) INFORMATION FOR SEQ ID NO:13:

## (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: unknown  
 (D) TOPOLOGY: linear

## (11) MOLECULE TYPE: protein

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Ser His Thr Asp Asn Ala Lys Ser Ser Asp Lys Glu Lys  
 1 5 10 15  
 His Arg Lys

## (2) INFORMATION FOR SEQ ID NO:14:

## (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: unknown  
 (D) TOPOLOGY: linear

## (11) MOLECULE TYPE: protein

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Cys Lys Asp Ser Glu Gly Arg Gly Ser Gly Asp Pro Gly Lys Lys Lys  
 1 5 10 15  
 Glu His Ile

## (2) INFORMATION FOR SEQ ID NO:15:

## (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: unknown  
 (D) TOPOLOGY: linear

## (11) MOLECULE TYPE: protein

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Asn Pro Glu Lys Lys Trp Val Arg Glu Tyr Ile Asn Ser Leu Glu Met  
 1 5 10 15  
 Ser

## (2) INFORMATION FOR SEQ ID NO:16:

## (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: linear

## (11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Lys Gln Lys Asn Val Gln Asp Ser Met Asp His Leu Asp Lys Gln Thr  
 1 5 10 15

Gln Thr Pro Lys Thr  
 20

## (2) INFORMATION FOR SEQ ID NO:17:

## (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: linear

## (11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Tyr Thr Leu Lys Pro Gln Thr  
 1 5

## (2) INFORMATION FOR SEQ ID NO:18:

## (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: linear

## (11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Tyr Ile Tyr Ser Leu Asp Thr Gln Tyr Ser Lys Val Leu Ala Leu Asn  
 1 5 10 15

Gln His Asn Pro Gly Ala Ser Ala Ala  
 20 25

(2) INFORMATION FOR SEQ ID NO:19:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:19:

1 Ile Leu Leu Ser Glu Leu Ser Arg Arg Arg  
5  
10

(2) INFORMATION FOR SEQ ID NO:20:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:20:

1 Leu Met Gly Val Ile Tyr Val Pro Leu Thr Asp Lys Glu Lys Glu Trp  
5  
10  
15 Ser Trp Lys

## (2) INFORMATION FOR SEQ ID NO:21:

## (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Glu Thr Ser Ser Leu Leu Lys Ile Gln Thr Leu Ala Gly His Gly  
 1 5 10 15

Arg Arg Leu

## (2) INFORMATION FOR SEQ ID NO:22:

## (1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Met Asn Ser Ser Val Pro Gly Asp Pro Met  
 1 5 10

CLAIMS

What is claimed is:

1. A fusion protein carrier segment comprising a non-naturally occurring hydrophobic sparingly soluble amino acid sequence.

2. The carrier segment of claim 1 wherein the amino acid sequence is substantially nonantigenic.

3. The carrier segment of claim 1 wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site).

4. The carrier segment of claim 1 wherein the carrier segment comprises no more than approximately 5% of the following amino acids: arginine, lysine, aspartic acid, glutamic acid, cysteine, tryptophan and methionine.

5. The carrier segment of claim 1 having a length at least about 65 amino acids long.

6. The carrier segment of claim 1 consisting of the sequence illustrated in Fig. 1 [SEQ. ID. 1].

7. The carrier segment of claim 1 consisting of the sequence illustrated in Fig. 3 [SEQ. ID. 2].

8. A vector comprising the amino acid sequence of claim 1.

9. A host cell transformed with the vector of claim



10. A substantially nonantigenic fusion protein carrier segment comprising a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence having a length at least about 65 amino acids long wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site).

11. The carrier segment of claim 10 consisting of the sequence illustrated in Fig. 1 [SEQ. ID. 1].

12. The carrier segment of claim 10 consisting of the sequence illustrated in Fig. 3 [SEQ. ID. 2].

13. A substantially nonantigenic fusion protein carrier segment comprising a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence having a length at least about 65 amino acids long, wherein the carrier segment comprises no more than approximately 5% of the following amino acids: arginine, lysine, aspartic acid, glutamic acid, cysteine, tryptophan and methionine.

14. A carrier protein conjugate comprising:

a. a first amino acid sequence, wherein the first amino acid sequence is at least about 65 amino acids long and the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine,

tryptophan and methionine (with the exception of methionine at the amino terminal site); and  
 b. a ligand fused to the first amino acid sequence.

15. The carrier protein conjugate of claim 14 wherein the ligand is a biologically active amino acid sequence, wherein the fusion protein exhibits biological activity of the second amino acid sequence.

16. The carrier protein conjugate of claim 15 wherein the ligand is a peptide derived from a procarcynotic, eucarcynotic, or environmentally derived source.

17. The carrier protein conjugate of claim 14 wherein the ligand is a hapten.

18. The carrier protein conjugate of claim 14 wherein the ligand is an epitope.

19. The carrier protein conjugate of claim 14 wherein the ligand has immunological binding activities.

20. An antigen for injecting into a host animal, comprising a carrier protein conjugate according to claim 14.

21. An amino acid sequence as illustrated in Fig. 1 [SEQ. ID. 1].

22. An amino acid sequence as illustrated in Fig. 3 [SEQ. ID. 2].

23. A non-naturally occurring carrier protein conjugate comprising an amino acid sequence as illustrated in Fig. 1 [SEQ. ID. 1] and a ligand fused to the amino acid sequence.

24. The carrier protein conjugate of claim 23, wherein the amino acid sequence is linked at the carboxyl terminal to the N-terminal of a peptide segment.

25. An expression vector comprising an amino acid sequence in a single reading frame with a coding sequence for an antigen, wherein the expression vector expresses a particle-forming fusion protein encoded by the amino acid sequence and a ligand, wherein the amino acid sequence is a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid, or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site).

26. A host cell transformed with the vector of claim 27. An adjuvant for administering an immunogen to a host animal, the adjuvant comprising a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence.

28. The adjuvant of claim 27 wherein the amino acid sequence is substantially nonantigenic.

29. The adjuvant of claim 27 wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid, or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site).

30. The adjuvant of claim 27 having a length at least about 65 amino acids long.

31. The adjuvant of claim 27 consisting of the sequence illustrated in Fig. 1 [SEQ. ID. 1].

32. The adjuvant of claim 27 consisting of the sequence illustrated in Fig. 3 [SEQ. ID. 2].

33. A process for producing an antibody to a ligand comprising:

- a. fusing a fusion protein carrier segment comprising a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence to the ligand to form a carrier protein conjugate.
- b. presenting the antigen; and
- c. producing the antibody to the ligand.

34. The process of claim 33 comprising presenting the antigen by an *in vivo* process of injecting the fusion protein into a host animal.

35. The process of claim 33 comprising presenting the antigen by an *in vitro* process of incubating the carrier protein conjugate with *in vitro* cultured cells.

36. Antibodies to the proteins produced according to the process of claim 33.

37. In an assay for determining the concentration of an anti-antigen antibody in a test sample, wherein (a) at least a carrier protein conjugate is attached to a solid phase as capture reagent and is contacted with the test sample for a time and under conditions suitable for antigen/antibody of complexes to occur, and (b) an indicator reagent comprised of a signal generating compound

and a specific binding member for the analyte is contacted with the complexes for time sufficient for a reaction to occur, wherein the signal generated is an indication of the presence of the anti-analyte antibody in the test sample, and wherein the improvement comprises attaching a fusion protein carrier segment comprising a non-naturally occurring hydrophobic sparingly soluble amino acid sequence to the solid phase as the capture reagent.

38. The assay of claim 37 further comprising identifying antibodies with epitopes defined by the peptide component of the carrier protein conjugate.

39. A process for vaccinating a host vertebrate animal with an immunogen, comprising:

a. preparing an immunogen comprising a

substantially nonantigenic fusion protein carrier segment containing a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence having a length at least about 65 amino acids long wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site); and

b. administering the carrier protein conjugate to the host vertebrate animal.

40. A process for vaccinating a host vertebrate animal with an immunogen, comprising:

- a. forming an immunogen comprising a non-naturally occurring carrier protein conjugate containing an amino acid sequence as illustrated in Fig. 1 [SEQ. ID. 1] and a ligand fused to the amino acid sequence; and
- b. administering the carrier protein conjugate to the host vertebrate animal.

41. A process for immunopurifying antibodies from a pool of antibody material, comprising:

- a. forming a substantially nonantigenic fusion protein carrier segment containing a non-naturally occurring, hydrophobic, sparingly soluble amino acid sequence having a length at least about 65 amino acids long wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site);
- b. incubating the antibody material with the carrier protein conjugate under binding conditions to bind the antibody material to the carrier protein conjugate to form an antibody/conjugate complex;
- c. separating out the antibody/conjugate complex;
- d. dissociating the antibody from the antibody/conjugate complex; and
- e. separating the antibody from the antibody/conjugate complex.

45. The process of claim 43 wherein the cleavage site includes amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site) and

44. The process of claim 43 where the fusion protein contains a cleavage site not found in the carrier segment (with the exception of methionine at the amino terminal site).

b. separating out the desired peptides.

43. A process for producing peptides, comprising:  
 a. incubating a fusion protein containing a non-naturally occurring hydrophobic sparingly soluble amino acid sequence, wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site), under conditions where the peptide bonds on the fusion protein are cleaved; and

42. The use of the carrier protein conjugate to purify antibodies specific to a subset of the original immunogen according to the process of claim 41, wherein the ligand of the carrier protein conjugate is a portion contained in the original immunogen.

other known cleavage sites from known proteases not included in the carrier segment.

46. The process of claim 43 comprising separating the carrier segment from the peptide after cleavage by precipitating the carrier segment.

47. The process of claim 43 comprising separating the carrier segment from the peptide after cleavage by adsorbing the carrier segment to a hydrophobic surface.

48. A protease inhibitor comprising a fusion protein containing a fusion protein carrier segment comprising a non-naturally occurring hydrophobic sparingly soluble amino acid sequence and a cleavage site for a protease, wherein the fusion protein is isolated and used as a competitive inhibitory substrate.

49. The protease inhibitor of claim 48 wherein the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid, glutamic acid, or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site).

50. A solid support having absorbed thereon a carrier protein conjugate comprising:

a. a first amino acid carrier sequence, wherein the first amino acid sequence is at least about 65 amino acids long and the amino acid sequence lacks at least two of the following amino acids selected from the group consisting of the following negatively or positively charged side chains of amino acids: arginine, lysine, aspartic acid,



glutamic acid; or uncharged side chains of the following amino acids: cysteine, tryptophan and methionine (with the exception of methionine at the amino terminal site); and b. a ligand fused to the first amino acid carrier sequence.

51. The solid support of claim 50 for use in diagnostic assays.

52. The solid support of claim 50 for use in affinity purification of proteins, wherein the ligand is adapted to selectively bind to a protein of interest.

53. The solid support of claim 50 for use in affinity separation of cells, wherein the ligand is adapted to selectively bind to a specific cell type or cells in a specific state of growth.

54. The solid support of claim 50 for use in studies of interactions between selected proteins, wherein the ligand contains a region of a protein which interacts with the selected region of a second protein.

55. In an assay for determining the concentration of an enzyme in a test sample, wherein (a) at least a carrier protein conjugate containing a ligand upon which the enzyme can act is attached to a solid phase and is contacted with the test sample for a time and under conditions suitable for the enzyme to act upon the substrate, and (b) indicator reagents capable of generating a signal change in response to the enzyme-catalyzed modification of the immobilized substrate is contacted with the complexes for time sufficient for a reaction to occur, wherein the signal generated is an indication of the presence of the enzyme in the test sample, and wherein the improvement comprises

attaching a recombinant fusion protein carrier segment comprising a non-naturally occurring hydrophobic sparingly soluble amino acid sequence to the solid phase as the capture reagent.

56. A test kit for use in detecting the presence of anti-antigen antibodies in a test sample, which test kit contains a container containing at least one protein specific for the anti-antigen antibody and, wherein the improvement comprises a container containing a non-naturally occurring hydrophobic sparingly soluble amino acid sequence, which is specific for the anti-antigen antibody.

57. An immunoassay kit for detecting a specific antigen, comprising in separate containers:

- a. a solid support having bound thereto one or more antibodies produced by the method of claim 33 that will specifically react with a desired antigen;
- b. buffer to remove unbound proteins;
- c. solutions for detection of bound analyte; and
- d. instructions for use.

Met Ala Ser Val Thr Gly Gly Gln Gln Val Gly Thr Asn Gln Gly His 1  
5  
10  
15  
20  
25  
30  
Gly Val Val Ala Ala Gly Thr Gly Leu Ala Leu Phe Leu His Val Phe  
35  
40  
45  
Gly Gly Thr Val Leu Thr Ala Phe Ala Gln His Thr Ser Val Thr Thr  
50  
55  
60  
Ser His Val Val His Ser Ile Ser Ser Ala Asn Ser Ala Gln Phe Pro  
65  
70  
75  
Val Leu Gly His Thr Gln Ala Ala Tyr Leu Ala Pro Gly Asn Gln


Fig. 1

Leu Gly Ile Pro Thr Ser Arg Asp Pro Gly Pro Leu Asp Ala Ala Ala  
1 5 10 15  
Cys Ile Ser Leu Ser Ile Leu  
20

Fig. 2

Met Ala Ser Val Thr Gly Gln Gln Val Gly Thr Asn Gln Gly His  
1 5 10 15  
Gly Val Val Ala Ala Gly Thr Gly Leu Ala Leu Phe Leu His Val Phe  
20 25 30  
Gly Gly Thr Val Leu Thr Ala Phe Ala Gln His Thr Ser Val Thr  
35 40 45  
Ser His Val Val His Ser Ile Ser Ser Ala Asn Ser Ala Gln Phe Pro  
50 55 60  
Val Leu Gly His Thr Gln Ala Tyr Leu Ala Pro Gly Asn Gln Leu  
65 70 75 80  
Gly Ile Pro Thr Ser Arg Asp Pro Gly Pro Leu Asp Ala Ala Cys  
85 90 95  
Ile Ser Leu Ser Ile Leu  
100

Fig. 3






Fig. 5a




Fig. 5b






Fig. 6

8/18






Fig. 7


9/18




10/18




11/18






12/18

13/18




14/18





15/18



16/18





Fig. 12

17/18



18/18




Fig. 14

# INTERNATIONAL SEARCH REPORT

International Application No  
PC/US 95/14518

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 C12N15/62 C07K16/42 G01N33/566 C12N1/21 C07K9/00 According to International Patent Classification (IPC) or to both national classification and IPC	
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C07K A61K C12Q G01N Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used)	
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>	
Category X	Citation of document, with indication, where appropriate, of the relevant passages WO, A, 92 02550 (CALIFORNIA BIOTECHNOLOGY INC.) 20 February 1992 cited in the application see page 6, line 3 - line 19 see page 9, line 10 - page 11, line 6 see page 14, line 15 - page 15, line 3 see page 23, line 10 - page 30, line 17; claims --- -/-
Relevant to claim No.	Patent family members are listed in annex. <input checked="" type="checkbox"/>
Special categories of cited documents: A. document defining the general state of the art which is not considered to be of particular relevance E. earlier document but published on or after the international filing date L. document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) O. document referring to an oral disclosure, use, exhibition or other means P. document published prior to the international filing date but later than the priority date claimed T. later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention X. document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone Y. document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. Z. document member of the same patent family	
Date of the actual completion of the international search 25 March 1996	Date of mailing of the international search report 02.04.96
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentkanal 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016 Authorized officer Montero Lopez, B	

# INTERNATIONAL SEARCH REPORT

Internal Application No  
PC/US 95/14518

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category :	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

X	<p>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 149, no. 2, 16 December 1987 ORLANDO, FL US, pages 431-436, YOSHIO YAMAMOTO ET AL. 'Engineering of the hydrophobic segment of the signal sequence for efficient secretion of human lysozyme by Saccharomyces cerevisiae' see the whole document</p> <p>MOLECULAR AND CELLULAR BIOLOGY, vol. 9, no. 8, August 1989 WASHINGTON US, pages 3400-3410, XP 000039574 JOHNNY K. NGSEE ET AL. 'Cassette mutagenesis analysis of the yeast invertase signal peptide: Effects on protein translocation' see page 3400, right column, paragraph 2 - see page 3401, left column, paragraph 1 see page 3403, right column, paragraph 2 - see page 3404, left column, paragraph 1 see page 3407, left column, paragraph 2 - page 3408, right column, paragraph 2</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 13, 5 May 1987 MD US, pages 6328-6333, LE T. DUONG ET AL. 'Synthetic signal peptide and analogs display different activities in mammalian and plant in vitro secretion systems' see page 6329, left column, paragraph 5 - right column, paragraph 1 see page 6329, right column, paragraph 4 - page 6330, left column, paragraph 1 see page 6332, left column, paragraph 3 - paragraph 4</p> <p>SCIENCE, vol. 243, no. 4895, 3 March 1989 DC, pages 1156-1159, XP 000268581 L.L. RANDALL ET AL. 'Unity in function in the absence of consensus in sequence: Role of leader peptides in export' see page 1157, left column, paragraph 2 - page 1158, left column, paragraph 1</p> <p>---</p> <p>---/---</p>	<p>1,3,4,8, 9,14-16, 25,26,43</p> <p>1,3,4,8, 9,14-16, 25,26,43</p> <p>1,3</p>
---	--	--

# INTERNATIONAL SEARCH REPORT

International Application No  
PC/US 95/14518

C (Continuation) DOCUMENTS C NSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BIOCHEMISTRY, vol. 26, no. 17, 25 August 1987 EASTON, PA US, pages 5267-5274, SHU-WHA LIN ET AL. 'Expression of human factor IX and its subfragments in Escherichia coli and generation of antibodies to the subfragments' cited in the application see abstract see page 5268, right column, paragraph 2 - page 5269, left column, paragraph 1 see page 5269, left column, paragraph 3 - page 5271, left column, paragraph 2 see page 5272, left column, paragraph 3 - page 5273, left column, paragraph 2 see page 5273, right column, paragraph 1</p>	<p>1,8-10, 13-16, 18-20, 23-26, 33-35, 39,40,43</p>

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/14518

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

PLEASE SEE ANNEX!

2. ☐ Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.



Remark: Although claim 33 partially, as far as an in vivo method, and claims 34, 39 and 40 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound.

International Application No  
PCT/US 95/14518

INTERNATIONAL SEARCH REPORT

Information on patent family members

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
---	---------------------	----------------------------	---------------------

W0-A-9202550	20-02-92	US-A-5202239	13-04-93
		CA-A-2089094	08-02-92
		EP-A-0542863	26-05-93
		JP-T-6504036	12-05-94
		US-A-5322930	21-06-94

L20 ANSWER 13 OF 47 PCTFULL COPYRIGHT 2003 Université  
 1991014458 PCTFULL ED 20020513  
 A FONCTIONNALISÉ COMPLEXAND  
 COMPLEXAND FONCTIONNALISÉ  
 BRECHBIELE, Martin, W.;  
 GANSOW, Otto, A.  
 THE UNITED STATES OF AMERICA, as represented by THE  
 SECRETARY, U.S. DEPARTMENT OF COMMERCE  
 English  
 Patent  
 PATENT INFORMATION:  
 PATENT ASSIGNEE(S):  
 LANGUAGE OF PUBL.:  
 DOCUMENT TYPE:  
 PATENT INFORMATION:  
 DESIGNATED STATES  
 W:  
 APPLICATION INFO.:  
 PRIORITY INFO.:  
 PI WO 9114458  
 DETD N, N', NI, NI-tetraacetic acid (EDTA)  
 types useful for binding metals, other than copper,  
 such as Indium. These compounds are useful for imaging  
 tumors.

metal  
 ions, or do not adequately bind the metal ions,  
 Examples of the usefulness of specific metal ions  
 follow\*  
 The usefulness of radionuclide materials in  
 cancer therapy is disclosed in the article, Kozak et  
 al., Radionuclide-Conjugated Monoclonal Antibodies: A  
 Synthesis of Immunology, in Organic Synthesis and  
 Nuclear Science, Trends.  
 The invention also includes Ligand-hapten  
 conjugates of the general Formula II and chelate-hapten  
 conjugates of the general Formula IIa.  
 A further embodiment includes the Ligand-  
 hapten conjugate wherein n is 2 and XI is @NH-Q\*  
 Another embodiment includes the Ligand hapten-  
 conjugate wherein Q is a protein, said protein being a  
 monoclonal antibody, chimeric antibody, or fragments  
 thereof,  
 A further embodiment of this invention is a  
 Ligand-hapten conjugate, as is drawn in  
 Formula II  
 (shown above), wherein three groups are @CH<sub>2</sub>COOH, and  
 the fourth is -H, n is an.  
 consisting of hormones, steroids, enzymes,  
 proteins, monoclonal or chimeric antibodies, and  
 fragments thereof. These haptens are desirable because  
 of their site specificity to tumors and/or various  
 organs of the body. The preferred hapten for use in  
 treating cellular disorders or various disease

conditions is a specific protein.

these pH values, thus, if a radiometal is used, providing an undesirable long term radiation does during metal chelate formation to any **happen** to which the **ligand** is **conjugated**. The pH region 4-7 is especially desirable for formation of trivalent metal ion chelate conjugated monoclonal antibodies in that the antibody is stable. . . . occurs at higher pH values, thus markedly simplifying the radiometal labeling of ligand conjugated antibodies or fragments as compared to such procedures for **happen conjugated DOTA ligands**.

An embodiment of the invention involves a **ligand-happen conjugate** of general formula II.

directly with the conjugate. The kinetics of the formation reactions for these compounds are so rapid that it is desirable to have the **ligand-happen-conjugate** available in the pharmacy immediately prior to use. The conjugate can then be mixed in the radionuclide to form the complex and, subsequently, the metal chelate conjugate formed can be purified, for example, by size exclusion high pressure liquid chromatography. A desirable **happen** for the **ligand conjugate** can be selected from the group consisting of hormones, steroids, enzymes, and proteins.

g, BI 212 I Y90 , and CU 67 to treat specific cellular disorders, A further embodiment of this invention is a **ligand-happen conjugate**, as is drawn in Formula II (shown above), wherein three groups are -CH<sub>2</sub> COOH, and the fourth is -

disorder. For example, Q can be a monoclonal antibody wherein the antibody is created and directed against an epitope found specifically on the **tumor cells**. Thus, when Y90 is transported to the antigen site and decays, a beta irradiation is produced. If desired, BI 212 can. . . .

is a diagnostic tool. Thus, when Pb 203 is linked by use of a chelate to a **happen**, which specifically localizes in a **tumor**, then that particular localization can be dimensionally mapped for diagnostic purposes in vivo by SPECT. Alternatively, the emission can be used in . . . .

The monoclonal antibody B72.3 binds specifically to a glycoprotein on LS-174T cells. This glycoprotein is also present in humans who have colon

**cancer.** This antibody is labeled with the ligand of compound 5 of Figure 1 as follows.

excipient and  
10 is used in a model system in athymic mice which have been implanted with LS174T cells to develop a **tumor** in the flank of the animal. The antibody localizes specifically to these **tumor** cells to deliver its radiation.

The antibody then localizes delivering the indium or gadolinium to the **tumor** site, and conventional gamma camera or magnetic resonance imaging techniques are employed to respectively visualize the **malignancy**.

CIMEN.

. . . wherein n is 2, X is -NH and M is a member selected from the group consisting of Eu and Tb.

9\* A **ligand-hapten conjugate** comprising:  
a general Formula II:

x  
n  
wherein three R groups are -CH<sub>2</sub>COOH and the fourth R group is -H,  
n is an integer from 1. . .

10 The **ligand-hapten conjugate** of claim 9 wherein n is 2 and XI is -NH-Q.

11 The **ligand-hapten conjugate** of claim 9 wherein Q is a protein, said protein being a monoclonal antibody, chimeric antibody, or fragments thereof.  
12e A chelate-hapten conjugate. . . ion being a member selected from the group of elements consisting of Bi, MO, Y., Cu., Ag, Au, Pt, and the Lanthanides.  
13\* The **ligand-hapten conjugate** of claim 9,  
where XI is -NH-L-Q wherein L is a covalent linking group.

L20



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 49/02, C12N 9/96 A61K 37/02, 39/44, C07K 17/02 C07E 19/00, C07D 257/02 C07J 43/00	A1	(43) International Publication Date: 3 October 1991 (03.10.91)
(11) International Publication Number: WO 91/14458		

(21) International Application Number: PCT/US91/01637	(22) International Filing Date: 14 March 1991 (14.03.91)	(30) Priority data: 498,320 26 March 1990 (26.03.90) US	(71) Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, U.S. DEPARTMENT OF COMMERCE [US/US]; 5285 Port Royal Road, Springfield, VA 22161 (US).	(72) Inventors: BRECHBIEL, Martin, W.; 3404 Monarch Lane, Annadale, VA 22003 (US), GANSOW, Otto, A.; 3003 Van Ness Street, N.W., # WS24, Washington, DC 20008 (US).
(74) Agents: HOLMAN, John, Clarke et al.; Flett, Jacobson, Cohn, Price, Holman & Stern, The Jenner Building, 400 Seventh Street, N.W., Washington, DC 20004 (US).		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), SI (European patent).		Published With international search report.

(54) Title: A FONCTIONALIZED COMPLEXAND

(57) Abstract

The present invention relates to macrocyclic chelates and methods of use thereof. Specifically, the invention relates to a substituted 1,4,7,10-tetraazacyclododecane triacetic acid wherein the three triacetic acids are linked at three of the nitrogens of the macrocycle, and a hydrogen is attached to the fourth nitrogen of the macrocycle. The chelate exists as a mixture of the four possible structures (or isomers). The present invention also relates to the various uses of these particular chelating agents.

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

**FOR THE PURPOSES OF INFORMATION ONLY**

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	LU	Luxembourg
BB	Barbados	FR	France	LK	Sri Lanka
BE	Belgium	GA	Gabon	LI	Liechtenstein
BF	Burkina Faso	GB	United Kingdom	KR	Republic of Korea
BC	Bulgaria	CN	Guinea	of Korea	
BJ	Benin	GR	Greece	KP	Democratic People's Republic
BR	Brazil	HU	Hungary	JP	Japan
CA	Canada	IT	Italy	SD	Sudan
CF	Central African Republic	KE	Kenya	SE	Sweden
CG	Congo	KE	Kenya	SN	Senegal
CH	Switzerland	KG	Kyrgyzstan	SU	Soviet Union
CI	Côte d'Ivoire	LA	Laos	TD	Chad
CM	Cameroon	LV	Latvia	TC	Togo
CS	Czechoslovakia	MC	Monaco	US	United States of America
DE	Germany				
DK	Denmark				

# **A FUNCTIONALIZED COMPLEXAND** **BACKGROUND OF THE INVENTION**

## **Technical Field**

The present invention relates to macrocyclic chelates and methods of use thereof. Specifically, the invention relates to a substituted 1,4,7,10-tetraazacyclododecane triacetic acid wherein the three triacetic acids are linked at three of the nitrogens of the macrocycle, and a hydrogen is attached to the fourth nitrogen of the macrocycle. The chelate exists as a mixture of the four possible structures (or isomers). The present invention also relates to the various uses of these particular chelating agents.

## **Background Information**

Macrocycles have been studied for their usefulness as chelating agents for numerous metal ions that have therapeutic, diagnostic, or other uses. A macrocycle of considerable value as a chelate is the 1,4,7,10-tetraazacyclododecane-N', N'', N''', N''''-linked to biomolecules to form delivery systems for the chelated metal ion to specific sites *in vivo*.

U.S. Patent 4,678,667 to Meares et al., discloses such chelating agents. The chelating agents of this patent can include a bifunctional DOTA compound that is a Cu(II) chelate. The usefulness is therefore limited to the effects of the copper metal ion. The synthesis is reportedly also lacks in efficiency resulting in low yields and not always reproducible results.

U.S. Patent 4,622,420 to Meares et al. discloses acyclic bifunctional chelating agents of the ethylenediamine N', N', N'', N''-tetraacetic acid (EDTA)



types useful for binding metals, other than copper, such as Indium. These compounds are useful for imaging tumors.

U.S. patent 4,652,519 to Warshawsky et al. also discloses EDTA type bifunctional chelates and a process for their production. These compounds were offered as an alternative to the Meares compounds discussed above.

U.S. Patents 4,453,106 and 4,474,509 to Gansow et al. disclose the use of metal chelate conjugated monoclonal antibodies and specific metal chelate conjugated monoclonal antibodies, respectively. These disclosures provide compounds and methods for treating cellular disorders. Advantages of the use of chimeric and monoclonal antibodies have been discussed (Morrison, S.L., Hospital Practice (Office Edition) 24:64-65, 72-74, 77-80 (1989). Radiometal chelate 24:64-65, 72-74, 77-80 (1989). Radiometal chelate conjugated monoclonal antibodies specific to a target cell are used to deliver alpha, beta, or Auger electron emitting metal ion. These disclosures are not related to DOTA compounds.

European Patent Application 0 088 695 to McKearn et al. discloses the oxidation of monoclonal antibody and linking of ligand by imine formation and subsequent cyanoborohydride reduction to form conjugates.

PCT application (WO 89/01476) to Parker et al. discloses macrocycle ligand/chelates and conjugates thereof.

European Patent Application 0 292 689 to Tweedle et al. discloses triacetate 1,4,7 10-tetraaza macrocycles but does not discuss the linkage of these

compounds to happens.

other U.S. patents which disclose various

chelating agents or conjugates include U.S.P.

4,442,305, U.S.P. 4,530,963, U.S.P. 4,732,974, and

U.S.P. 4,585,559.

The value of having a ligand conjugate to

chelat metal ions of therapeutic, diagnostic, or other  
uses lies in their commercial importance. This

commercial importance is created by the fact that many  
metal ions have desirable characteristics, but the

delivery systems lack specificity to target the metal  
ions, or do not adequately bind the metal ions.

Examples of the usefulness of specific metal ions

follow.

The usefulness of radionuclide materials in

cancer therapy is disclosed in the article, Kozak et

al., "Radionuclide-Conjugated Monoclonal Antibodies: A

Synthesis of Immunology, in Organic Synthesis and

Nuclear Science," Trends in Biotechnology 4(10): 259-

264 (1985). This article discusses the use of antibody  
conjugates to deliver either alpha or beta radiation.

Other uses for chelated metal ions are

discussed in Magerstadt et al. "Gd(DOTA): An

Alternative to Gd(DTPA) as a  $T_1/2$  Relaxation Agent for  
NMR Imaging or Spectroscopy," Magnetic Resonance in

Medicine 3:808-812 (1986). Specifically, this article

discloses the usefulness of gadolinium as a relaxation

agent for NMR imaging.

The efficacy of a linking group, within

30 chelated metal complexes, has been discussed by Paik et  
al., J. Nucl. Med. 30:1693-1701 (1989).

- Other articles which may be of som interest include: McMurry et al., "Template and Stepwise Synthesis of a Macrobicyclic Catechoylamide Ferric Ion Sequestering Agent," J. Amer. Chem. Soc. 109: 3451-53
- 5 (1987), Raymond et al., "Macrocyclic Catechol Containing Ligands," Pure & Appl. Chem. 60: 545-48 (1988), McMurry et al., "Macrobicyclic Ion (III) Sequestering Agents," J. Am. Chem. Soc. 109: 7196-98 (1987), McMurry et al., "Molecular Recognition and
- 10 Metal Ion Template Synthesis," Science 244: 938-43 (1989), Kiggin et al., "Functionalized Oligocyclic Large Cavities- A Novel Siderophore," Angew. Chem. Int. Ed. Engl. 23: 714-15 (1984), Kiggin et al., "Large Oligocyclic Cavities for Strong Cation Complexation,
- 15 Tetrahedron 42: 1859-72 (1986), Sun et al., "New Multidentate Ligands. 28. Synthesis and Evaluation of New Macrocyclic Ligands Containing Bidentate Endocyclic Catechol Donor Groups," Inorg. Chem. 25: 4780-85 (1985), Moi et al., "The Peptide Way to Macrocyclic
- 20 Bifunctional Chelating Agents: Synthesis of 2-(p-Nitrobenzyl) -1,4,7,10- Tetraazacyclododecane -N, N', N'', N''' -Tetraacetic Acid and Study of Its Yttrium (III) Complex, " J. Am. Chem. Soc. 110:6266-67 (1988), and Cox et al., "Synthesis of a Kinetically Stable
- 25 Yttrium-90 Labelled Macrocycle Antibody Conjugate," J. Chem. Soc., Chem. Commun., pp. 797-98 (1989).


All patents and publications referred to herein are hereby incorporated by reference.

- The industry is lacking a macrocyclic chelate
- 30 that can be efficiently produced in high yields, that can be linked to proteins, and that has desirable chelating qualities for numerous metal ions wherein the

formation kinetics thereof and reaction conditions required for metal complexation are favorable for use with monoclonal antibodies.

# SUMMARY OF THE INVENTION

5 The invention is the ligand and its metal chelates having a general Formula of I and Ia, respectively:



wherein three of the R groups are  $-\text{CH}_2\text{COOH}$  with the fourth R being kept as  $-\text{H}$ ;  
 n is an integer from 1 to 5;  
 X equals  $-\text{NO}_2$  or  $-\text{NH}_2$ ; and  
 20 and M is a metal ion being a member selected from the group of elements consisting of Y, In, Bi, Pb, Cu, Ag, Au, Pt, and the Lanthanides.

A preferred embodiment includes the situation where, in the ligand, X is either  $-\text{NO}_2$  or  $-\text{NH}_2$ , and n  
 25 is an integer from 1 to 2.

Another preferred embodiment includes the situation where, in the chelate, X is either  $-\text{NO}_2$  or  $-\text{NH}_2$ , and n is 1 to 2.



An additional embodiment includes the  
 30 situation where, in the chelate described in the paragraph directly above, M is a member selected from the group consisting of Bi, Pb, Y, Cu, Gd, Eu and Tb.

A further embodiment includes the situation where, in the chelate,  $n$  is 2,  $X$  is  $-NH_2$ , and  $M$  is a member selected from the group consisting of  $Pb^{203}$ ,  $Pb^{212}$ ,  $Bi^{212}$ ,  $Y^{90}$ , and  $Cu^{67}$ .

- 5 An additional embodiment includes the chelate described in the paragraph directly above wherein  $M$  is a member selected from the group consisting of  $Pb^{212}$  and  $Bi^{212}$ .

- Another embodiment includes the situation  
10 where, in the chelate,  $n$  is 2,  $X$  is  $-NH_2$ , and  $X$  is  $-NH_2$ , and  $M$  is a member selected from the group consisting of  $Eu$  and  $Tb$ .

- The invention also includes ligand-hapten  
conjugates of the general Formula II and chelate-hapten  
15 conjugates of the general Formula IIa:



25

II

IIa

- wherein three of the  $R$  groups are  $-CH_2COOH$  with the fourth  $R$  group being kept as  $-H$ ;  
 $n$  is an integer from 1 to 5;  
 $X'$  equals  $-NH-Q$  where  $Q$  is selected from the group  
30 consisting of hormones, steroids, enzymes and proteins, a subset of proteins being monoclonal antibodies, chimeric antibodies, and fragments thereof;

and M is a metal ion being a member selected from the group consisting of Y, In, Bi, Pb, Cu, Ag, Au, Pt, and the Lanthanides.

A further embodiment includes the ligand-hapten conjugate wherein n is 2 and X' is -NH-Q.

Another embodiment includes the ligand hapten-conjugate wherein Q is a protein, said protein being a monoclonal antibody, chimeric antibody, or fragments thereof.

A further embodiment of this invention is a ligand-hapten conjugate, as is drawn in Formula II (shown above), wherein three groups are  $-\text{CH}_2\text{COOH}$ , and the fourth is -H, n is an integer from 1 to 5, and X' is -NH-L-Q where Q is a hapten chosen from the group consisting of hormones, steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof, and L is a covalent linking group.

An additional embodiment of this invention is a chelate-hapten conjugate, as is drawn in Formula IIa (shown above), wherein three groups are

$-\text{CH}_2\text{COOH}$ , and the fourth is -H, n is an integer from 1 to 5, X' is -NH-L-Q where Q is a hapten selected from the group consisting of hormones, steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof, M is a metal ion selected from the group consisting of Bi, Pb, Y, Cu, Ag, Au, Pt and the lanthanides, and L is a covalent linking group.

In either of the two embodiments directly above, L may be an organic radical or a substituted aliphatic hydrocarbon chain, optionally interrupted by one or more hetero atoms selected from -O- or

-S-, or by one or more -NR'- groups (where R' is a hydrogen atom or a C<sub>1</sub>-C alkyl group), -CONR'- groups, -NR'CO- groups, cycloaliphatic groups, aromatic groups, or heteroaromatic groups, or a mixture thereof.

5           The invention also includes methods for using these compounds for treatment of cellular disorders and for diagnostic tests. Thus, the above compounds may be used as therapeutic and diagnostic agents.

#### BRIEF DESCRIPTION OF THE DRAWINGS

10           Figure 1 illustrates the chemical pathway used to produce the preferred embodiment of the invention.

#### DETAILED DESCRIPTION OF THE INVENTION

Compounds of this invention include the substituted 1,4,7,10 tetraazacyclododecane triacetic  
15 acid represented in the general Formula I shown above or specifically by compound 5 of Figure 1. The general formula is a 12 membered ring tetraaza macrocycle, with the nitrogens in the 1,4,7,10 positions. The acetic acid groups are attached to three of the nitrogens, and  
20 a hydrogen is attached to the remaining secondary nitrogen. This description encompasses all four possible structures or isomers contained in the mixture. Furthermore, each of the nitrogens is bridged by an ethylene group.

25           The substituted triacetic acid ligands represented by Formula I complexes metals (Formula Ia). Metal complexes are formed by placing the ligand into solution with an appropriate metal salt having the metal to be chelated. Metal salts have to be selected  
30 so as to prevent the hydrolysis of the metal. Also, reaction conditions in an aqueous medium have to be chosen such that the metal is not hydrolyzed. For

example, a lead nitrate, bismuth iodide complex, or yttrium acetate salts can be used to form a metal chelate with lead, bismuth, or yttrium, respectively. General examples of suitable salts include any soluble  
5 divalent metal complex or any trivalent metal complex that is not hydrolyzed at pH 4 to about 9. The most desirable metal ions for chelation with general Formula I are members from the group consisting of bismuth, lead, copper, yttrium, platinum, gold, silver, gallium,  
10 and any of the elements of the lanthanide series. The most desirable elements of the lanthanide series are (1) gadolinium, for use in NMR imaging and as a relaxation agent in NMR imaging, and (2) terbium and (3) europium, because of their use as chromophores in  
15 time resolved fluorescence spectroscopy. These fluorescent compounds can be useful in an in vitro diagnostic assay.

The aniline substituent of compound 5 is desirable as a substituent that can be used to  
20 conjugate the compound to haptens. The aniline group can be linked to an oxidized carbohydrate on the protein as an imine, and the linkage can subsequently be reduced to an amine by cyanoborohydride.

The haptens suitable for linking with the  
25 compounds of general Formula I or Ia can vary widely. The most desirable haptens are members selected from the group consisting of hormones, steroids, enzymes, proteins, monoclonal or chimeric antibodies, and fragments thereof. These haptens are desirable because  
30 of their site specificity to tumors and/or various organs of the body. The preferred hapten for use in treating cellular disorders or various disease



conditions is a specific protein type, a monoclonal antibody or chimeric antibody, or fragments thereof.

In Formulas Ia and IIa, the compounds of this invention can have a value of  $n$  equal to an integer from 1 to 5. In a preferred embodiment,  $n$  equals 2. It is desirable for  $n$  to equal 2 versus 1 because the chelating ligand is separated from the protein more and possesses increased free rotation. The increased free rotation allows a metal to chelate with the macromolecule more easily. When  $n$  is 3 or greater, the synthesis of the compound becomes lengthy.

Figure 1 illustrates the preferred reaction pathway or process for forming the compound of this invention. The process first provides a cyclic triamide with a substituent on the carbon backbone framework of the molecule. The embodiment of Figure 1 has  $n=1$  as the initial substituent for linkage. The process then provides a tetraaza macromolecule having the substituent in the 2 position as shown. Alkylation with bromoacetic acid forms the three nitrogen to carbon bonds of the three carboxymethylene substituents.

The desired diactive ester 1 is formed sequentially from iminodiacetic acid. The amine is first blocked using the reagent BOC-ON or any other suitable blocking agent such as EMOC, in the presence of triethylamine which serves to deprotonate the starting material. The subsequent nitrogen blocked diacetic acid or other such nitrogen blocked compound is then coupled to N-hydroxysuccinimide, or any of the suitable compounds such as phenols, or N-hydroxydicarboximides which form a reactive ester. The choice of compounds which form active esters or

blocking groups in within the scope of the art. The coupling is done by a carbodiimide. This step produces the nitrogen blocked active ester.

Ring formation under high dilution conditions  
5 between amino acid amides (compounds 1a) with the nitrogen blocked active ester (compound 1) is then performed. This step forms the triamide macrocycle (compound 2). The amine nitrogen of compound 2 is deblocked with hydrochloric acid in dioxane. This  
10 forms the HCl salt of the triamide macrocycle. The salt is then reduced with borane/tetrahydrofuran. The resulting borane adduct is cleaved by hydrochloric acid to form the substituted tetraaza macrocycle (compound 3). This macrocycle can then be alkylated with three  
15 equivalents of haloacetic acid in the presence of base to form a nitrobenzyl tetraaza macrocycle triacetate (compound 4). The nitro group of compound 4 can be reduced with hydrogen over a palladium on carbon catalyst to produce the aniline or the aminobenzyl  
20 structure depicted as compound 5.

The chelating agent formed by the tri-alkylation of the cyclen described in the process of Figure 1 is novel and separate from those previously described in that, when reacted with trivalent metal  
25 ions, an electrically neutral (zero charged) metal chelate is formed. The advantages of such zero charged chelates in medical applications is well understood and has been recently described, for example, by Tweedle, et. al. (E.P.A. 0 292 698), and includes reduced  
30 osmolality of the complex and increased lipophilicity, hence solubility in lipid tissues. This, in turn, confers an increased ability of the metal complexes to

clear from the interior of cells. This last feature is of importance since often monoclonal antibodies are catabolized into normal liver cell interiors, and for diagnostic imaging in the abdomen, such clearance from normal liver cells is to be desired.

A particular advantage of the tri-alkylated ligands of Formula I lies in their ability to rapidly form metal chelates at aqueous solution pH values 4-7. The more complex DOTA macrocycles, in which the hydrogen that is attached to the secondary nitrogen of Formula I is replaced by a carboxymethylene group, are harder to label with metals since they react exceedingly slow with trivalent metals such as indium or yttrium at these pH values, thus, if a radiometal is used, providing an undesirable long term radiation dose during metal chelate formation to any hapten to which the ligand is conjugated. The pH region 4-7 is especially desirable for formation of trivalent metal ion chelate conjugated monoclonal antibodies in that the antibody is stable therein, and the metal ions are less susceptible to hydrolysis as occurs at higher pH values, thus markedly simplifying the radiometal labeling of ligand conjugated antibodies or fragments as compared to such procedures for hapten conjugated DOTA ligands.

In its preferred embodiment, the coupling of compound 5 to antibodies is through imine formation with oxidized carbohydrate on protein followed by in situ reduction to the amine. An advantage of this methodology is that when coupling to proteins and, in particular, when coupling to antibodies, the carbohydrate of the antibody can be oxidized prior to

the coupling reaction. The aniline reacts with the aldehyde that is formed on the protein. The imine that is formed can be reduced by cyanoborohydride to form a covalent amine linkage to the antibody that is site  
5 specific. This position is distant from the antigen binding sites of the monoclonal antibody and thus minimizes any deleterious effects of the protein modification.

An embodiment of the invention involves a  
10 ligand-hapten conjugate of general Formula II. This conjugate complexes metal ions. For complexation, especially of radioactive metals, it is desirable to expose metal ions to the protein conjugate in a concentrated metal solution for a short a period of  
15 time as possible. Certain metals, such as divalent metal ions, react rapidly and directly with the conjugate. The kinetics of the formation reactions for these compounds are so rapid that it is desirable to have the ligand-hapten conjugate available in the  
20 pharmacy immediately prior to use. The conjugate can then be mixed in the radionuclide to form the complex and, subsequently, the metal chelate conjugate formed can be purified, for example, by size exclusion high pressure liquid chromatography. A desirable hapten for  
25 the ligand conjugate can be selected from the group consisting of hormones, steroids, enzymes, and proteins.

The most commercially useful embodiments of the invention are metal chelate-hapten conjugates  
30 having the general Formula IIa where: (1) n is an integer from 1 to 5, (2) X is -NH-Q- with Q being a hapten selected from the group consisting of hormones,

steroids, proteins, monoclonal antibodies, chimeric antibodies, and fragments thereof, and (3) M is a metal ion being selected from the group of elements consisting of Bi, Pb, Cu, Ag, Au, Y, Pt, and the lanthanides. These chelate conjugates can deliver radioactive metal ions such as  $Pb^{212}$ ,  $Bi^{212}$ ,  $Y^{90}$ , and  $Cu^{67}$  to treat specific cellular disorders. A further embodiment of this invention is a ligand-hapten conjugate, as is drawn in Formula II (shown above), wherein three groups are  $-CH_2COOH$ , and the fourth is  $-H$ , n is an integer from 1 to 5, and  $X'$  is  $-NH-L-Q$  where Q is a hapten chosen from the group consisting of hormones, steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof and L is a covalent linking group.

An additional embodiment of this invention is a chelate-hapten conjugate as is drawn in Formula IIa (shown above) wherein three groups are  $-CH_2COOH$ , and the fourth is  $-H$ , n is an integer from 1 to 5,  $X'$  is  $-NH-L-Q$  where Q is a hapten selected from the group consisting of hormones, steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof, M is a metal ion selected from the group consisting of Bi, Pb, Y, Cu, Ag, Au, Pt and the lanthanides, and L is a covalent linking group.

In either of the two embodiments directly above, L may be an organic radical or a substituted aliphatic hydrocarbon chain, optionally interrupted by one or more hetero atoms selected from  $-O-$  or  $-S-$ , or by one or more  $-NR'-$  groups (where  $R'$  is a hydrogen atom or a  $C_{1-C}$  alkyl group),  $-CONR'-$  groups,  $-NR'CO-$  groups, cycloaliphatic groups, aromatic groups,

or heteroaromatic groups, or a mixture thereof.

The invention includes a process for treating cellular disorders. The process uses the chelate conjugate with a hapten having a selective binding site  
5 at the cellular disorder. For example, Q can be a monoclonal antibody wherein the antibody is created and directed against an epitope found specifically on the tumor cells. Thus, when  $Y^{90}$  is transported to the antigen site and decays, a beta  
10 irradiation is produced. If desired,  $Bi^{212}$  can be introduced in those cases where the disorder to be treated, such as with leukemic cells, can be reached within the 1 hour half-life of the isotope. Most desirably, at least 95 percent of the radionuclide  
15 remains in the chelate. In an acidic medium, such as the stomach, at least about 70 percent is retained.

The invention also includes a process for diagnostic testing. This process uses a chelate conjugate having general Formula IIa wherein M is  
20 selected from the group consisting of  $Pb^{203}$ ,  $In^{111}$ ,  $Ga^{67}$ ,  $Ga^{68}$ . The usefulness of metal ions for both in vitro and in vivo diagnostic procedures is disclosed in U.S. Patent 4,454,106.

The most desirable embodiment of this  
25 diagnostic process uses  $Pb^{203}$ .  $Pb^{203}$  has a 52.1 hour half-life as a gamma emitter.  $Pb^{203}$  has a unique property in that it decays in a high percentage by single photon emission. This gamma emission is preferred and dominant over all other emissions. This  
30 single photon emission makes  $Pb^{203}$  useful for single photon emission computed tomography (SPECT) which is a diagnostic tool. Thus, when  $Pb^{203}$  is linked by use of

a chelate to a hapten, which specifically localizes in a tumor, then that particular localization can be dimensionally mapped for diagnostic purposes in vivo by SPECT. Alternatively, the emission can be used in vitro in radioimmunoassay.

The present invention can be illustrated by the use of the following non-limiting examples.

EXAMPLE 1

Synthesis of p-Nitrobenzyl 1,4,7,10 tetraazacyclododecane triacetic acids

The cyclen (compound 3 of Figure 1) was alkylated at 45°C with three sequential additions of 1 equivalent of bromoacetic acid in the presence of 5 M sodium hydroxide. The base was added via an autoburette, and the pH of the reaction solution was maintained at 8.5. The reaction was allowed to stir at 45°C overnight after the final addition. The following day the solution was acidified to pH 2.0 with 3 N HCl. The solution was loaded onto a 2.6 x 30 cm AG50WX8 200/400 mesh H<sup>+</sup> form ion exchange column and washed with water until the eluant was neutral. The crude product was eluted from the column with one liter of 2 M NH<sub>4</sub>OH. The solution was rotary evaporated to a solid. The solid was taken up in water (25 mL total with rinsing ) and loaded onto a 1.6 x 20 cm AGLWX8 200/400 mesh HOAc form ion exchange column. The product was eluted with a two liter gradient of 0.0 to 0.3 M HOAc. The relevant fractions were combined, concentrated to 25 mL, and then freeze dried to give a fluffy white solid product.

EXAMPLE 2Labeling of Antibody With Metal Chelate

The procedures and reagents described above for the preferred embodiment of making the compounds are used for this example.

The monoclonal antibody B72.3 binds specifically to a glycoprotein on LS-174T cells. This glycoprotein is also present in humans who have colon cancer. This antibody is labeled with the ligand of compound 5 of Figure 1 as follows:

One mL of B72.3 (10 mg/mL) was cooled in an ice bath and combined with 20  $\mu$ L of 2.5 M sodium acetate (pH 6). Sodium periodate ( $\text{NaIO}_4$ , 3.5-4.7 mg, Aldrich) was added, giving a  $\text{NaIO}_4$  concentration of 16.22 mM. After the solid was dissolved, the clear solution was left on ice in the refrigerator for 1 1/2 hrs. The solution was then passed through a 2 x 10 cm Sephadex G-50 column, eluted with acetate-buffered saline (pH 6). Ten fractions (1 mL each) were collected, and the concentration of B72.3 in each fraction was determined by UV absorption at 220 nm. The fractions containing oxidized B72.3 (6.7-9.0 mg in 2.2 mL) were collected and reacted with excess compound 5 at a molar ratio of 1:50-60. The mixture was mixed, allowed to stand at room temperature for one hr, and finally left in the refrigerator overnight. The next day, sodium cyanoborohydride (Aldrich, 20-25  $\mu$ L of 1 M solution) was added to the chelate-conjugated B72.3 to reduce the Schiff base to the saturated amine. This mixture was allowed to stand at room temperature for 4-5 hr.



Before labeling with metal, the protein is dialyzed against a solution comprising 0.02 M N-morpholinoethanesulfonic acid and 0.01 M NaCl at pH 5.9.

- 5           The protein in solution is labeled with  $\gamma^{90}$  by reaction with an acetate solution of the isotope followed by passage through a TSK 3000 size exclusion column. This is a high pressure liquid chromatography technique. The compound is mixed with an excipient and  
10 is used in a model system in athymic mice which have been implanted with LS-174T cells to develop a tumor in the flank of the animal. The antibody localizes specifically to these tumor cells to deliver its radiation.

15


#### EXAMPLE 3

##### In Vivo Use of the Labeled Protein Conjugate

- The protein conjugate in solution is labeled with indium or gadolinium, and the chelate conjugate is injected or introduced into body fluids of a mammal.  
20 The antibody then localizes delivering the indium or gadolinium to the tumor site, and conventional gamma camera or magnetic resonance imaging techniques are employed to respectively visualize the malignancy.

CLAIMS:

1. A ligand comprising:  
a general Formula I:

**I**


wherein three of the R groups are  $-\text{CH}_2\text{COOH}$  with the fourth R group being  $-\text{H}$ ;

wherein n is an integer from 1 to 5; and

X is either  $-\text{NO}_2$  or  $-\text{NH}_2$ .

2. The ligand of claim 1 wherein n is 1 to 2 and X is either  $-\text{NO}_2$  or  $-\text{NH}_2$ .

3. A chelate comprising a general Formula Ia:

**Ia**

wherein three of the R groups are  $-\text{CH}_2\text{COOH}$  with the fourth R group being  $-\text{H}$ ;

wherein  $n$  is an integer from 1 to 5; and

$X$  is either  $-\text{NO}_2$  or  $-\text{NH}_2$ ;

and  $M$  is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, Cu, Au, Ag, Pt, Ga, In, and the Lanthanides.

4. The chelate of claim 3 wherein  $n$  is 1 to 2 and  $X$  is either  $-\text{NO}_2$  or  $-\text{NH}_2$ .


5. The chelate of claim 4 wherein  $M$  is a member selected from the group consisting of Bi, Pb, Y, Cu, Gd, Eu, and Tb.

6. The chelate of claim 3 wherein  $n$  is 2,  $X$  is  $-\text{NH}_2$ , and  $M$  is a member selected from the group consisting of  $\text{Pb}^{203}$ ,  $\text{Pb}^{212}$ ,  $\text{Bi}^{212}$ ,  $\text{Y}^{90}$ , and  $\text{Cu}^{67}$ .

7. The chelate of claim 6, wherein  $M$  is a member selected from the group consisting of  $\text{Pb}^{212}$  and  $\text{Bi}^{212}$ .

8. The chelate of claim 4, wherein  $n$  is 2,  $X$  is  $-\text{NH}_2$  and  $M$  is a member selected from the group consisting of Eu and Tb.

9. A ligand-hapten conjugate comprising:  
a general Formula II:



II

wherein three R groups are  $-\text{CH}_2\text{COOH}$  and the fourth R group is  $-\text{H}$ ;


n is an integer from 1 to 5; and

X' consists of  $-\text{NH}-\text{Q}$  with Q being a hapten selected from the group of hormones, steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof.

10. The ligand-hapten conjugate of claim 9 wherein n is 2 and X' is  $-\text{NH}-\text{Q}$ .

11. The ligand-hapten conjugate of claim 9 wherein Q is a protein, said protein being a monoclonal antibody, chimeric antibody, or fragments thereof.

12. A chelate-hapten conjugate comprising: a general Formula IIa:



IIa

wherein three R groups are  $-\text{CH}_2\text{COOH}$  and the fourth is  $-\text{H}$ ;

n is an integer from 1 to 5; and

X' is  $-\text{NH}-\text{Q}$  with Q being a hapten selected from the group consisting of hormones, steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof; and

M is a metal ion being a member selected from the group of elements consisting of Bi, Pb, Y, Cu, Ag, Au, Pt, and the Lanthanides.

13. The ligand-hapten conjugate of claim 9, where X' is -NH-L-Q wherein L is a covalent linking group.

14. The covalent linking group, L, of claim 13 wherein L is an organic radical or a substituted aliphatic hydrocarbon chain.

15. The substituted hydrocarbon chain of claim 14 where said chain may be interrupted by one or more hetero atoms selected from the group consisting of -O- or -S-, or by one or more -NR' groups, where R' is a hydrogen atom or a C<sub>1</sub>-C alkyl group, -CONR' groups, -NR'CO- groups, cycloaliphatic groups, aromatic groups or heteroaromatic groups, or a mixture thereof.

16. The chelate-hapten conjugate of claim 12 wherein X' is -NH-L-Q wherein L is a covalent linking group.



17. The covalent linking group L of claim 15 wherein L is an organic radical or a substituted aliphatic hydrocarbon chain.

18. The substituted hydrocarbon chain of claim 17 wherein said chain may be interrupted by one or more hetero atoms selected from the group consisting of -O- or -S-, or by one or more -NR' groups, where R' is a hydrogen atom or a C<sub>1</sub>-C alkyl group, -CONR' groups, -NR'CO- groups, cycloaliphatic groups, aromatic groups or heteroaromatic groups, or a mixture thereof.

19. The method of using the chelate-hapten conjugate of claim 12 where said conjugate is administered to the patient as a diagnostic or

therapeutic agent.

20. The method of using the chelate-hapten conjugate of claim 15 wherein said conjugate is administered to the patient as a diagnostic or therapeutic agent.



R= H.  $\text{CH}_2\text{CO}_2\text{H}$   
IN WHICH THERE IS ONLY ONE H  
AND THERE ARE THREE  $\text{CH}_2\text{CO}_2\text{H}$   
4

M

**SUBSTITUTE SHEET**

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/01637

## I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): A61K 49/02; C12N 9/96; A61K 37/02, 39/44; C07K 17/02; C07F 19/00; C07D 257/02; C07J 43/00  
US CL: 424/1.1, 9, 85, 91, 94.3; 435/188; 514/12, 21; 530/388, 390, 391, 408, 409; 534/10; 540/474; 552/502

## II. FIELDS SEARCHED

Minimum Documentation Searched *	
Classification System	Classification Symbols
U.S.	424/1.1, 9; 435/188; 514/12, 21; 530/388, 390, 391, 408, 409; 534/10; 540/474; 552/502; 556/110

Documentation Searched other than Minimum Documentation  
to the extent that such documents are included in the fields searched \*

Structure search in file Registry, File CA

## III. DOCUMENTS CONSIDERED TO BE RELEVANT \*

Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	US, A, 4,885,363 (TWEEDLE ET AL.) 05 December 1989. See Abstract and column 4.	1-20
Y	US, A, 4,472,509 (GANSOW ET AL.) 18 September 1984. See column 3, lines 17-40 and abstract.	1-20
Y	J. Am. Chem. Soc. Volume 110, issued 1988, MOI ET AL.; "The Peptide Way to Macrocyclic Bifunctional Chelating Agents: Synthesis of 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N'',N''',-teraacetic Acid and Study of Its Yttrium(III) Complex". Pages 6266-6267, see 2nd column on page 6266.	1-20
A,P	US, A, 4,994,560 (KRUPER JR. ET AL.) 19 February 1991. See column 9.	1-20
A	WO, A, 89/01475 (PARKER ET AL.) 23 February 1989. See page 8.	1-20

\* Special categories of cited documents: <sup>10</sup>

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claims or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document mentioned in the same patent type.

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

21 June 1991

Date of Mailing of this International Search Report

18 JUL 1991

International Searching Authority

ISA/US

Signature of Authorized Officer

*Kay K. Kim*  
Kay K. Kim, PhD

(vsh)



FURTHER INFORMATION

N CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers \_\_\_\_\_ because they relate to subject matter <sup>12</sup> not required to be searched by this Authority, namely:
  
2. ☐ Claim numbers \_\_\_\_\_ because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>13</sup>, specifically:
  
3. ☐ Claim numbers \_\_\_\_\_ because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

See attachment sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. 1-20
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all search fees could not be searched without a short justifying an additional fee, the International Searching Authority did not make payment of any additional fee.

Remarks on Protest

- ☒ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ATTACHMENT TO PCT/ISA 10  
VI. OBSERVATIONS WHERE UNITY  
OF INVENTION IS LACKING - page 1

Group I. Claims 1-8, drawn to chelator ligand, classified in Classes 534 and 540, subclasses 10+ and 474 respectively.

Group II. Claims 9-18, drawn to ligand-hapten conjugates, classified in Classes 435, 530 or 540, subclasses 188, 388+ or 474 respectively.

Group III. Claims 19 and 20 drawn to methods of use of the second group of products above, classified in Classes 424 and 514, subclasses 1.1, 9, 94.3; and 12 and 14 respectively.

Invention of Group II encompasses distinct conjugates as represented by the following: A) a species of conjugates wherein the hapten Q is hormones or steroids, B) species of conjugates wherein the hapten Q is enzymes, C) species of ligand wherein the hapten Q is proteins or antibodies.

HPS Trailer Page  
for

# Waik-Up Printing

UserID: K

Printer: cm1\_9e12\_gbeptr

## Summary

Document	Pages	Printed	Missed	Copies
WO009114458	29	29	0	1
Total (1)	29	29	0	-